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1. INTRODUCTION 
1.1. Traditional System of Medicines1, 2, 3  
India has a rich heritage of traditional medicine and the traditional health care 
system have been flourishing for many centuries. traditional medicine, defined by the 
WHO as "medical knowledge systems that developed over generations within various 
societies before the era of modern medicine, including the health practices, approaches, 
knowledge and beliefs incorporating plant, animal and mineral-based medicines, 
spiritual therapies, manual techniques and exercises, applied singularly or in 
combination to treat, diagnose and prevent illnesses or maintain well-being" is used 
globally and has rapidly growing economic importance. In developing countries, 
traditional medicine is often the only accessible and affordable treatment available. In 
Latin America, the WHO regional office for the Americas (AMRO/PAHO) reports that 
71% of the population in China and 40% of the population in Columbia has used 
traditional medicine. 
In many Asian countries traditional medicine is widely used, even though 
western medicine is often readily available. In Japan, 60-70% of allopathic doctors 
prescribe traditional medicines for their patients. In the US the number of visits to 
providers of Complementary Alternative Medicine (CAM, codified herbal medicine) 
now exceeds by far the number of visits to all primary care physicians. 
Ayurveda 
Ayurvedic medicine is a system of traditional medicine native to the Indian 
subcontinent and practiced in other parts of the world as a form of traditional medicine. 
In Sanskrit, the words ayurveda consist of the word say us, means "longevity", and 
veda, means "related to knowledge" or "science". Evolving throughout its history, 
ayurveda remains an influential system of medicine in South Asia. The earliest 
literature on Indian medical practice appeared during the vedic period in India. The 
Susruta Samhta-and the Charaka Samhta- where influential works on traditional 
medicine during this era. Ayurveda is considered to be a form of complementary and 
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alternative medicine (CAM) in the western world, where several of its methods, such as 
the use of herbs, massage, and yoga, are applied on their own as a form of CAM 
treatment.  
Ayurveda is the ancient (before 2500 B.C.)  Indian system of health care 
involving a holistic view of man, his health, and illness. Ayurvedic treatment of a 
disease consists of salubrious use of drugs, diets, and certain practices. Medicinal 
preparation is invariably complex mixtures, based mostly on plant products. Around 
1,250 plants are used in various ayurvedic preparations. 
Many Indian medicinal plants have come under scientific scrutiny since the 
middle of the nineteenth century, although in a sporadic fashion. 
The first significant contribution from ayurvedic material medica came with the 
isolation of the hypertensive alkaloids from the sarpagandha plant (Rauwolfia 
serpentina), valued in ayurveda for the treatment of hypertension, insomnia and 
insanity. This was the first important ancient-modern concordance in ayurvedic plants. 
According to ayurveda, all objects in the universe including human body are 
composed of five basic elements (Panchamahabhutas) namely, earth, water, fire, air and 
vaccuum (ether). There is a balanced condensation of these elements in different 
proportions to suit the needs and requirements of different structures and functions of 
the body matrix and its parts. The growth and development of the body matrix depends 
on its nutrition, i.e. on food. The food, in turn, is composed of the above five elements, 
which replenish or nourish the like elements of the body after the action of bio-fire 
(agni). The tissues of the body are the structural whereas humours are physiological 
entities, derived from different combinations and permutations of Panchamahabhutas. 
Treatment of the disease consists in avoiding causative factors responsible for 
disequilibrium of the body matrix or of any of its constituent parts through the use of 
Panchkarma procedures, medicines, suitable diet, activity and regimen for restoring the 
balance and strengthening the body mechanisms to prevent or minimize future 
occurrence of the disease. 
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Use of these three measures is done in two ways. In one approach of treatment 
the three measures antagonize the disease by counteracting the etiological factors and 
various manifestations of the disease. 
 In the second approach the same three measures of medicine, diet and activity 
are targeted to exert effects similar to the etiological factors and manifestations of the 
disease process. These two types of therapeutic approaches are respectively known as 
Vipreeta and Vipreetarthkari treatments. 
Siddha 
Siddha system is one of the oldest systems of medicine in India. The term siddha 
means achievements and siddhars were saintly persons who achieved results in 
medicine. Eighteen Siddhars were said to have contributed towards the development of 
this medical system. Siddha literature is in tamiland it is practiced largely in tamil 
speaking part of India and abroad. The siddha system is largely therapeutic in nature. 
This principles and doctrines of this system, both fundamental and applied, have 
a close similarity to ayurveda, with specialization in iatro-chemistry. According to this 
system the human body is the replica of the universe and so are the food and drugs 
irrespective of their origin. Like ayurveda, this system believes that all objects in the 
universe including human body are composed of five basic elements namely, earth, 
water, fire, air and sky. The food, which the human body takes and the drugs it uses are 
all, made of these five elements. The proportion of the elements present in the drugs 
vary and their preponderance or otherwise is responsible for certain actions and 
therapeutic results. As in ayurveda, this system also considers the human body as a 
conglomeration of three humours, seven basic tissues and the waste products of the 
body such as faeces, urine and sweat. The food is considered to be basic building 
material of human body which gets processed into humours, body tissues and waste 
products. The equilibrium of humours is considered as health and its disturbance or 
imbalance leads to disease or sickness. This system also deals with the concept of 
salvation in life. The exponents of this system consider achievement of this state is 
possible by medicines and meditation. 
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The siddha system is capable of treating all types of disease other than 
emergency cases. In general, this system is effective in treating all types of skin 
problems particularly psoriasis, STD, urinary tract infections, diseases of liver and 
gastro intestinal tract, general debility, postpartum anemia, diarrhoea and general fevers. 
Unani 
Unani system of medicines originated in Greece and is based on the teachings of 
Hippocrates and Gallen and it developed in to an elaborate medical system by Arabs, 
like Rhazes, Avicenna, Al-Zahravi, Ibne-Nafis and others. Unani medicines got 
enriched by imbibing what was best in the contemporary systems of traditional 
medicines in Egypt, Syria, Iraq, Persia, India, China and other Middle East countries. In 
India, unani system of medicine was introduced by Arabs and soon it took firm roots. 
The Delhi Sultans (rulers) provided patronage to the scholars of unani system and even 
enrolled some as state employees and court physicians. During 13th and 17th century 
A.D. Unani medicine had its hey-day in India. During the British rule, unani system 
suffered a setback due to withdrawal of State Patronage, but continued to be practiced 
as the masses reposed faith in the system. It was mainly Sharif family in Delhi, the 
Azizi family in Lucknow and the Nizam of Hyderabad due to whose efforts unani 
medicine survived during the British period. In India, the concept of research in unani 
system of medicine was originally perceived by Masih-ul-Mulk Hakim Ajmal Khan in 
the 1920s. A versatile genius of his time, Hakim Ajmal Khan spotted Dr. Salimuzzaman 
Siddiqui- a chemist- for undertaking chemical studies on some important medicinal 
plants used in unani medicine. Dr. Siddiqui undertook the task visualized by Masih-ul-
Mulk and his discovery of medicinal properties of a plant, commonly known as Asrol 
(Pagalbooti), led to sustained research that established the unique efficacy of this plant 
known all over the world as Rauwolfia serpentina, in neurovascular and nervous 
disorders, such as hypertension, insanity, schizophrenia, hysteria, insomnia and 
psychosomatic conditions, etc., 
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Homoepathy 
Homeopathy, founded by a German physician Samuel Hahnemann in 1790, is 
based on the idea that ‘like cures like’; that is substances that cause certain symptoms in 
a healthy person can also cure those same symptom in someone who is sick. This so 
called low of similar gives homeopathy its name ‘homeo’ for similar ‘pathy’ 
designating disease. In this experiment Hahnemann developed a method of 
‘potentizing’ homeopathic remedies by diluting them in a water-alcohol solution and 
then vigorously shaking the mixtures.  
The result convinced him that a high degree of dilution not only minimizes the 
side effects of the remedies but also simultaneously enhances their medical efficacy. 
Most Homeopathic remedies have undergone ‘proving’ or medical observation in which 
healthy individuals are given doses of undiluted homeopathic substances. 
Mental, emotional, psychic and other details of the patients are most important. 
This leads the physician to a better understanding of which remedy will best suits a 
particular set of symptoms. Over the past 200 years, providing for almost 2,000 
substances have been conducted. 
International diversity 
Traditional medicine practices have been adopted in different cultures and 
regions without the parallel advance of international standards and methods for 
evaluation. 
National policy and regulation 
Many countries have not national policies for traditional medicine. Regulating 
traditional medicine products, practices and practitioners is difficult due to variations in 
definitions and categorizations of traditional medicine therapies. A single herbal 
product could be defined as a food, a dietary supplement or an herbal medicine, 
depending on the country. This disparity in regulations at the national level has 
implications for international access and distribution of products. 
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Safety, effectiveness and quality 
Scientific evidence from tests done to evaluate the safety and effectiveness of 
traditional medicine products and practices is limited. While evidence shows that 
acupuncture, some herbal medicines and some manual therapies (e.g. massage) are 
effective for specific conditions, further study of products and practices is needed. 
Requirements and methods for research and evaluation are complex. For example, it can 
be difficult to assess the quality of finished herbal products. The safety, effectiveness 
and quality of finished herbal medicine products depend on the quality of their source 
materials (which can include hundreds of natural constituents), and how elements are 
handled through production processes. 
Knowledge and sustainability 
The expanding herbal product market could drive over-harvesting of plants and 
threaten biodiversity. Poorly managed   collection and cultivation practices could lead 
to the extinction of endangered plant species and the destruction of natural resources. 
Efforts to preserve both plant populations and knowledge on how to use them for 
medicinal purposes is needed to sustain traditional medicine. 
Patient safety and use 
Many people believe that because medicines are herbal (natural) or traditional 
they are safe (or carry no risk for harm). However, traditional medicines and practices 
can cause harmful, adverse reactions if the product or therapy is of poor quality, or it is 
taken in appropriately or in conjunction with other medicines. Increased patient 
awareness about safe usage is important, as well as more training, collaboration and 
communication among providers of traditional and other medicines. 
1.2. Novel Drug Delivery System4 
The method by which a drug is delivered can have a significant effect on its 
efficacy. Some drugs have an optimum concentration range within which maximum 
benefit is derived, and concentrations above or below this range can be toxic or produce 
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no therapeutic benefit at all. On the other hand, the very slow progress in the efficacy of 
the treatment of severe diseases, has suggested a growing need for a multidisciplinary 
approach to the delivery of therapeutics to targets in tissues. From this, new ideas on 
controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity, 
immunogenicity, biorecognition, and efficacy of drugs were generated. These new 
strategies, often called drug delivery systems (DDS), are based on interdisciplinary 
approaches that combine polymer science, pharmaceutics, bioconjugate chemistry, and 
molecular biology. 
To minimize drug degradation and loss, to prevent harmful side-effects and to 
increase drug bioavailability and the fraction of the drug accumulated in the required 
zone, various drug delivery and drug targeting systems are currently under 
development. Among drug carriers one can name soluble polymers, microparticles 
made of insoluble or biodegradable natural and synthetic polymers, microcapsules, 
cells, cell ghosts, lipoproteins,liposomes and micelles. The carriers can be made slowly 
degradable, stimuli-reactive (e.g., pH- or temperature-sensitive), and even targeted (e.g., 
by conjugating them with specific antibodies against certain characteristic components 
of the area of interest). Targeting is the ability to direct the drug-loaded system to the 
site of interest. Two major mechanisms can be distinguished for addressing the desired 
sites for drug release: (i) passive and (ii) active targeting. An example of passive 
targeting is the preferential accumulation of chemotherapeutic agents in solid tumors as 
a result of the enhanced vascular permeability of tumor tissues compared with healthy 
tissue. A strategy that could allow active targeting involves the surface fictionalization 
of drug carriers with ligands that are selectively recognized by receptors on the surface 
of the cells of interest. Since ligand–receptor interactions can be highly selective, this 
could allow a more precise targeting of the site of interest. 
 Controlled drug release and subsequent biodegradation are important for 
developing successful formulations. Potential release mechanisms involve: (i) 
desorption of surface-bound /adsorbed drugs; (ii) diffusion through the carrier matrix; 
(iii) diffusion (in the case of nanocapsules) through the carrier wall; (iv) carrier matrix 
erosion; and (v) a combined erosion /diffusion process. The mode of delivery can be the 
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difference between a drug’s success and failure, as the choice of a drug is often 
influenced by the way the medicine is administered. Sustained (or continuous) release 
of a drug involves polymers that release the drug at a controlled rate due to diffusion out 
of the polymer or by degradation of the polymer over time. Pulsatile release is often the 
preferred method of drug delivery, as it closely mimics the way by which the body 
naturally produces hormones such as insulin. It is achieved by using drug-carrying 
polymers that respond to specific stimuli (e.g., exposure to light, changes in pH or 
temperature). 
For over 20 years, researchers have appreciated the potential benefits of 
nanotechnologyin vast providing improvement in drug delivery and drug targeting. 
Improving delivery techniques that minimize toxicity and improve efficacy 
offers great potential benefits to patients, and opens up new markets for pharmaceutical 
and drug delivery companies. Other approaches to drug delivery are focused on 
crossing particular physical barriers, such as the blood brain barrier, in order to better 
target the drug and improve its effectiveness; or on finding alternative and acceptable 
routes for the delivery of protein drugs other than via the gastro-intestinal tract, where 
degradation can occur. 
1.2.1. Topical delivery 
 Over the last decades, the treatment of illness has been accomplished by 
administrating drugs to human body via various routes namely oral, sublingual, rectal, 
parental, topical, inhalation etc. Topical delivery can be defined as the application of a 
drug containing formulation to the skin to directly treat cutaneous disorders (e.g. acne) 
or the cutaneous manifestations of a general disease (e.g. psoriasis) with the intent of 
containing the pharmacological or other effect of the drug to the surface of the skin or 
within the skin. Semi-solid formulation in all their diversity dominate the system for 
topical delivery, foams, spray, medicated powders, solution, and even medicated 
adhesive systems are in use. 
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Topical delivery includes two basic types of product: 
• External topical that are spread, sprayed, or otherwise dispersed on to cutaneous 
tissues to cover the affected area 
• Internal topical that are applied to the mucous membrane orally, vaginally or on  
anorectal tissues for local activity 
 For the most part topical preparations are used for the localized effects at the site 
of their application by virtue of drug penetration into the underlying layers of skin or 
mucous membranes. Although some unintended drug absorption may occur, it is sub 
therapeutics quantities and generally of minor concern. 
1.2.2. Advantages of Topical Drug Delivery Systems 
• Avoidance of first pass metabolism 
• Convenient and easy to apply 
• Avoidance of the risks and inconveniences of intravenous therapy and of the 
 varied conditions of absorption, like pH changes, presence of enzymes, gastric 
 emptying time etc., 
• Achievement of efficacy with lower total daily dosage of drug by continuous  
 drug input 
• Avoids fluctuation in drug levels, inter- and intrapatient variations 
• Ability to easily terminate the medications, when needed 
• A  relatively large area of application in comparison with buccal or nasal cavity 
• Ability to deliver drug more selectively to a specific site 
• Avoidance of gastro-intestinal incompatibility 
1.2.3. Disadvantages of Topical Drug Delivery Systems 
• Skin irritation of contact dermatitis may occur due to the drug and/or excipients 
• Poor permeability of some drugs through the skin 
• Possibility of allergenic reactions 
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• Can be used only for drugs which require very small plasma concentration for  
 action 
• Enzyme in epidermis may denature the drugs 
 
1.3. Transdermal Drug Delivery Systems 5, 6 
The TDDS are defined as self-contained, discrete dosage forms which, when 
applied to the intact skin, deliver the drug(s), through the skin, at a controlled rate to the 
systemic circulation. Transdermal drug delivery is a viable administration route for 
potent, low-molecular weight therapeutic agents which cannot withstand the hostile 
environment of gastrointestinal tract and/or subject to considerable first-pass 
metabolism by the liver. 
1.3.1. Advantages of TDDS: 
• Transdermal medication delivers a steady infusion of a drug over an extended 
period of time. Adverse effects or therapeutic failures frequently associated 
with intermittent dosing can be avoided. 
• Transdermal delivery can increase the therapeutic value of many drugs by 
avoiding specific problems associated with the drug e.g., gastro-intestinal 
irritation, low absorption, decomposition due to hepatic “first-pass” effect, 
formation of metabolites that cause side effects, short half-life necessitating 
frequent dosing etc. 
• The simplified medication regimen leads to improved patient compliance and 
reduced inter-and intra-patient variability. 
• Self-administration is possible with these systems. 
• The drug input can be terminated at any point of time by removal of drug 
application from the skin surface. 
• Substitute’s oral administration when route is unsuitable as in case of 
vomiting, diarrhoea and in unconscious patients. 
• Achievement of efficacy with lower total daily dosage of drug by continuous 
drug input. 
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• Provides utilization of drugs with short biological half-life, narrow therapeutic 
window. 
• Avoids risk and inconveniences of intravenous therapy. 
• Reduces the chances of over- or under dosing through the prolonged, 
preprogrammed delivery of drug at the required therapeutic rate. 
1.3.2. Disadvantages of TDDS: 
• The drug must have some desirable physicochemical properties for penetration 
through Stratum corneum (SC) and if the drug dosage required for therapeutic 
value is more than 10 mg/day, the transdermal delivery will be very difficult if 
not impossible. Daily doses of less than 5mg/day are preferred. 
• Skin irritation or contact dermatitis due to the drug, excipients and penetration 
enhancers used to increase percutaneous absorption of the drug is another 
limitation. 
• Clinical need is another area that has to be examined carefully before a decision 
is made to develop a transdermal product. 
• The barrier function of the skin changes from one site to another on the same 
person, from person to person and with age. 
• Poor permeability of drugs through the skin. 
• Enzymes in epidermis may denature the drugs. 
• Drugs that require high blood levels cannot be administered. 
1.4.The Skin 7,8 
To understand the concept of TDDS, it is important to review the structural and 
biochemical features of human skin and those characteristics which contribute to the 
barrier function and the rate of drug access into the body via skin. The skin is one of the 
most extensive organs of the human body covering an area of about 2m2 in an average 
human adult. This multilayered organ receives approximately one-third of the blood 
circulating through the body. It has varied functions and properties. 
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 The dry composition of the horny layer is 75-85% protein; the bulk of the 
remainder of the substance is a complicated mixture of lipids, this combination of 
ceratnocytes with interspersed spidermal lipids form a water proof moisture barrier that 
minimizes trans epidermal water loss (TEWL) to keep moisture in the skin. It is 
approximately 10-20um thick and acts as protective membrane preventing water loss 
from the skin and limiting the entry of chemicals from the environment. Stratum 
corneum consists of lipids which are made up of ceramaides and neutral lipids such as 
free fatty acids free sterols and triglycerides, the remainder is made up of phospholipids, 
glycosphingolipids and cholesterol sulphate. Below the Stratum corneum are the other 
layers of the epiderm is the stratum lucidum, stratum granulosum, and stratum 
spinosum and stratum germinativum, together these layers constitute the viable 
epidermis. 
1.4.3. Dermis: 
The dermis is vascularized and the thickest of all the layers (3-5mm thick). It 
possesses sweat glands, hair follicles, nerve endings and lymph vessels and acts as the 
systemic absorption site for drugs. The dermis is located between the hypodermis and 
the epidermis. An average human skin is known to contain on the average 40-70 hair 
follicle and 200-300 sweat glads on each square cm of skin area. 
1.4.4.  Hypodermis: 
The hypodermis, which is subcutaneous fat layer that functions as insulation and 
padding for the body. The hypodermis is the deepest section of the skin as shown in the 
(Fig No.1). 
 The hypodermis refers to the fat tissue below the dermis that insulates the body 
from cold temperatures and provides shock absorption. Fat cells of the hypodermis also 
store nutrients and energy. 
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1.5. Kinetics of Skin Permeation9 
Transdermal permeation of a drug involves the following steps: 
1. Sorption by Stratum corneum. 
2. Penetration of drug through viable epidermis. 
3. Uptake of the drug by the capillary network in the dermal papillary layer 
 
This permeation can be possible only if the drug possesses certain physiochemical 
properties. 
The rate of permeation across the skin (dQ/dt) is given by: 
dt
dQ = Ps(cd – cr)------------------(1) 
Where, 
Cd – Concentration of the permeant in donor phase (Stratum corneum) 
Cr – Concentration of the permeant in receptor phase (systemic circulation). 
P2 – Overall permeability co-efficient of the skin. 
Permeability coefficient is given by the relationship: 
Ps = 
2
22
h
DK =------------------(2) 
Where, 
 K2 - Partition co-efficient of penetrant. 
 D2 - Apparent diffusivity of penetrant 
h1 - Overall thickness of the skin 
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Thus permeability coefficient (P2) may be constant if K d and h terms are 
constant under a given set of conditions. A constant rate of drug permeation is achieved 
if   Cd>> C2  
Then equation (1) becomes: 
td
dQ = P2 Cd------------------(3) 
The rate of skin permeation is constant provided the magnitude of C4 remains 
fairly constant throughout the course of skin permeation. For keeping C4 constant the 
drug should be released from the device at R4 (release rate of drug) which is either 
constant or greater than R1 (the rate takes up the drug)  i.e. R1>> R2 Since R1>> R2, the 
drug concentration on the skin surface C4 is maintained at a level equal to or greater 
than the equilibrium solubility of the drug in the SC, C, i.e. Cd>> Cr 
Therefore a maximum rate of skin permeation is obtained and is given by the 
equation: 
(dQ/dt) m = P2 C2……………..(4) 
From the above equation it can be seen that the maximum rate of skin 
permeation depends upon the skin permeability coefficient P2 and the equilibrium 
solubility in the SC, C2. Thus skin permeation appears to be SC limited. 
1.5.1. Enhancement of Transdermal Delivery: 
Skin is an important site of drug application for both local and systemic effects. 
However in skin, the SC is the main barrier for drug penetration. Penetration 
enhancement technology is a challenging development that would increase the number 
of drugs available for transdermal administration. Significant  advancement has been 
made, in the last two decades, in achieving a better control in the delivery through the 
skin. Research has been directed to find ways of delivering different types of drug 
molecule with the help of different enhancement techniques (Fig No.3) 
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A strategy to enhance the skin permeation in the present study is the use of 
permeation enhancers. One of the easiest approaches to enhance the permeation rate is 
the use of penetration enhancers. These are the substances added to pharmaceutical 
formulation in ordered to increase the membrane permeation or absorption rate of a co-
administered drug. 
1.5.2. Ideal characteristics of chemical penetration enhancers: 
Ideally, penetration enhancers reversibly reduce the barrier resistance of the SC 
without damaging the viable cells. Some of the more desirable properties for 
penetration enhancers acting within the skin have been given as: 
9 They should be non-toxic, non-irritating and non-allergenic 
9 They would ideally work rapidly, and the activity and duration of effect should 
be both predictable and reproducible 
9 They should have no pharmacological activity within the body  i.e. should not 
bind to receptor sites 
9 The penetration enhancers should work unidirectionally, i.e. should allow 
therapeutic agents into the body whilst preventing the loss of endogenous 
material from the body 
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9 When removed from the skin, barrier properties should return both rapidly and 
fully 
9 The penetration enhancers should be appropriate for formulation into diverse 
topical preparations, thus should be compatible with both excipients and drugs 
9 They should be economicacally acceptable with an appropriate skin feel 
 
1.5.3. Mechanism of Chemical Penetration Enhancement10 
Penetration enhancers may act by one or more of three main mechanisms. 
1. Disruption of the highly ordered structure of Stratum corneum lipid. 
2. Interaction with intercellular protein. 
3. Improved partition of the drug, co-enhancer or solvent into the Stratum coneum. 
 
1.5.4. Different Classes of Permeation Enhancers are as follows: 
1.5.4.1. Sulfoxides 
Dimethylsulfoxide (DMSO) is an effective penetration enhancer that promotes 
permeation by reducing skin resistance to drug molecules or by promotion of drug 
partitioning from the dosage form. It has been postulated that DMSO denatures the 
intercellular structural proteins of the SC, or promotes lipid fluidity by disruption of the 
ordered structure of the lipid chains. Along with these, DMSO may alter the physical 
structure of the skin by elution of lipid, lipoprotein and nucleoprotein structures of the 
Stratum corneum. 
1.5.4.2. Alcohols 
Alcohols may influence transdermal penetration by a number of mechanisms. 
The alkyl chain length of the alkanols is an important parameter in the promotion of 
permeation enhancement. Lower molecular weight alkanols are thought to act as 
solvents, enhancing the solubility of drugs in the matrix of the Stratum corneum. 
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1.5.4.3. Polyols 
The activity of propylene glycol is thought to result from salvation of a keratin 
within the SC; the occupation of proteinaceous hydrogen bonding sites reducing drug-
tissue binding and thus promoting permeation. 
1.5.4.4. Alkanes 
Long chain alkanes (C2-C16) have been shown to enhance skin permeability by 
nondestructive alteration of the SC barrier. 
1.5.4.5. Fatty acids 
Selective perturbation of the intercellular lipid bilayers in the SC appears to be 
the major mode of enhancing activity of the fatty acids. 
1.5.4.6. Esters 
Esters such as ethyl acetate are relatively polar, hydrogen bonding compounds 
that may enhance permeation in a similar manner to the sulphoxides and formamides by 
penetrating into the SC and increasing the lipid fluidity by disruption of lipid packing. 
1.5.4.7. Amines and amides: 
¾ Urea 
Urea promotes transdermal permeation by facilitating hydration of the SC and 
by the formation of hydroplic diffusion channels within the barrier.  Cyclical 
urea permeation enhancers are biodegradable, non-toxic molecules consisting 
of a polar parent moiety and a long chain alkyl ester group. 
¾ Dimethyl acetamide and dimethyl formamide 
These compounds are less potent penetration enhancing chemical alternatives 
to DMSO. At low concentrations their activity as enhancers is a result of 
partitioning into the keratin regions. At higher concentrations they increase 
lipid fluidity by disruption of lipid packing as a result of salvation shell 
formation around the polar head groups of the lipids. 
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¾ Pyrrolidones 
Pyrrolidone and its derivatives are reported to interact with both keratin and 
with lipids in the skin. Azone is known to show significant accelerant effects 
at low concentrations for both hydrophilic and hydrophobic drugs and is one 
of the few enhancers that have been  developed commercially. Differential 
scanning calorimetric studies have shown that azone affects lipid structures of 
the SC.  In addition, azone is reported to decrease transition temperatures 
within lipid bilayers to induce formation of a liquid phase with a resultant 
increase in lipid fluidity. 
1.5.4.8. Terpenes 
Terpenes are found inessential oils, and are compounds comprising of only 
carbon, hydrogen and oxygen atoms, but which are not aromatic. Numerous 
terpenes have long been used as medicines as well as flavoring and fragrance 
agents. Terpenes are generally considered as less toxic and have less irritant 
effects compared to surfactants and other skin penetration enhacers, and some 
terpenes have been characterized as Generally Recognized As Safe (GRAS) by 
the US FDA. They have high percutaneous enhancement ability, reversible 
effect on the lipids of SC, minimal percutaneous irritancy at low concentrations 
(1-5%). Moreover, a variety of terpenes have been shown to increase 
percutaneos absorption of both hydrophilic and lipophilic drugs.11 Both the 
mono-and sesquiterpenes are known to increase  percutaneous absorption of 
compounds by increasing diffusivity of the drug and/or by disruption of the 
intercellular lipid barrier. A further mechanism of activity that has been 
postulated is that the terpenoids increase electrical conductivity of tissues 
thereby opening polar pathways within the Stratum corneum. 
1.5.4.9. Surface active agents: 
Surface active agents function primarily by adsorption at interfaces and thus 
interact with biological membranes contributing to the overall penetration 
enhancement of  compounds. Cationic surfactants are more destructive to skin 
tissues causing a greater increase in flux than anionic surfactants. The latter, in 
turn, produce greater increases in flux than non-ionic surfactants.  
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Anionic surfactants may function by alteration of the barrier function of the SC 
as a result of removal of water soluble agents that act as plasticizers. Sodium lauryl 
sulphate has been implicated in reversible lipid modification with resultant 
disorganization of the SC and enhanced permeation. In addition, non-ionic surfactants 
are purported to be able to emulsify sebum, consequently altering partitioning potential 
of drugs in favour of enhanced permeation. The permeation enhancement generated by 
these compounds may be dependent on the ability of drug to partition between the free 
and bound or micellar form of the enhancer. 
1.5.3.10. Cyclodextrins 
Cyclodextrins are bio-compatible substances that can form inclusion complexes 
with lipophilic drugs with a resultant increase in their solubility, particularly in aqueous 
solutions. However, cyclodextrins alone were determined be to less effective as 
penetration enhancers than when combined with fatty acids and propylene glycol. 
1.6. Basic Components of Transdermal Drug Delivery Systems11 
The components of transdermal devices include: 
1. Backing layer 
2. Drug containing reservoir 
a. Polymer matrix 
b. Drug 
c. Permeation enhancers 
d. Plasticizers 
3. The release control layer 
4. The adhesive 
5. The peel strip. 
1.  Backing layer 
Backing layer must be impermeable to drugs and enhancers if used and as a 
result it is usually unpermeable to water vapor that is occlusive. 
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 The most commonly used backing materials are alupoly, polyester, 
polyethylene co-extruded films or metalized polyester laminated with polyethylene. The 
film can be either clear flesh colored or metalized.  Backing membranes are flexible and 
provide a good bond to the drug reservoir prevent drug from leaving the dosage form 
through the top and accept printing. It protects the product during use on the skin. 
2. Drug containing reservoir: 
A) Polymer Matrix: 
 The Polymer controls the release of the drug from the device. The development 
of transdermal systems requires judicious selection of a polymeric material or a series 
of polymers whose diffusive characteristic will be such that a desirable permeation rate 
of a specific drug or other bio-active agent can be obtained. 
The polymer should meet the following requirements: 
i) Molecular weight, glass transition temperature and chemical functionality  
      of polymer must allow proper diffusion and release of the specific drug. 
ii) The polymer should not chemically react with the drug. 
iii) The polymer and its degradation products must be non-toxic. 
iv) The polymer should not decompose on storage or use of the device. 
v) The polymer should be inexpensive. 
vi) The polymer must be easy to manufacture and it should yield itself into the 
desired product and should allow incorporation of large quantities of active 
component without deterioration of its mechanical properties. 
Polymers that can be used in the transdermal formulations are: 
a) Natural Polymers: 
Cellulose derivatives, Zein, Gelatin, Shellac, Waxes, Proteins, Gums and their  
derivatives, Natural rubber, Starch etc. 
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b) Synthetic Elastomers: 
    Polybutadieine, Hydrin rubber, Polysiloxane, Silicone rubber, Nitrile,   
Acrylonitrile, Butyl rubber,  Styrenebutadieine rubber, Neoprene etc. 
 
c) Synthetic Polymers: 
Polyvinyl alcohol, Polyvinyl chloride, Polyethylene, Polypropylene, 
Polyacrylate, Polyamide, Polyurea, Polyvinylpyrrolidone, Poly methylmethacrylate, 
etc., 
B) Drug: 
 For successfully developing a TDDS, the drug should be chosen with great care. 
The following are some of the desirable properties of a drug for transdermal delivery. 
Physicochemical properties: 
1. The drug should have a molecular weight less than approximately 1000 daltons. 
2. The drug should have affinity for both lipophilic and hydrophilic phases. 
3. The drug should have a low melting point. 
Biological properties: 
1. The drug should be potent with a daily dose of the order of a few mg/day. 
2. The halflife (tn) of the drug should be short. 
3. The drug must not induce a cutaneous irritant or allergic response. 
4. Drugs which degrade in the g.i.t or/are inactivated by hepatic first pass effect are 
suitable candidates for transdermal delivery. 
5. Tolerance to the drug must not develop under the near zero order release profile 
of transdermal delivery. 
6. Drugs which have to administered for along period of time or which cause 
adverse effects to non target tissues can also be formulated for transdermal 
delivery. 
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C) Permeation Enhancers: 
Discussed in detail in section 1.5. 
D) Plasticizers: 
These are used to prevent the films from becoming brittle.12 An ideal plasticizer 
should possess the following properties. 
1. Should not show any pharmacological action of its own. 
2. Should be chemically and physically stable. 
3. Should be compatible with the drug and the formulated components. 
4. Should be colourless, colorless and tasteless. 
5. Should be non-toxic, non-allergenic & non-irritant. 
3.Release control layers: 
           The rate controlling membrane can be either a micro-porous or a non-porous 
polymeric membrane with defined drug permeability. The membrane can be constituted 
with any of the polymers discussed earlier. 
4. Adhesives: 
           The fastening of all transdermal devices to the skin has so far been done by using 
a pressure sensitive adhesive which can be positioned on the face of the device or in the 
back of the device and extending peripherally. Both adhesive systems should fulfill the 
following criteria. 
(i) Should adhere to the skin aggressively, should be easily removed. 
(ii) Should not leave an unwashable residue on the skin. 
(iii) Should not irritate or sensitize the skin. 
 
The face adhesive system should also fulfill the following criteria. 
i) Physical and chemical compatibility with the drug, excipients and enhancers of 
the device of which it is a part. 
ii) Permeation of drug should not be affected. 
iii) The delivery of simple or blended permeation enhancers should not be affected. 
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5. Peel Strip: 
The peel strip prevents loss of drug that has migrated into adhesive layer during 
storage and also protects the finished device against contamination. Polyester foils and 
metalized laminates are the choices. 
6. Packet: 
Packet guards the patches against drug loss and contamination on storage. The 
patches are individually packed in heat sealed foil pouches. 
1.7 . Approaches used in the Development of TDDS 12 
 Several techniques have been successfully developed to provide a mechanism of 
rate control over the release and transdermal permeation of drugs. These are three 
types of  devices currently available in the market. To be precise, there are two 
concepts in the design namely, the reservoir type and the matrix type. 
1.7.1 Different technologies employed in the development of TDDS: 
I. Polymer Membrane Permeation controlled TDDS: 
 
In this system the drug reservoir is sandwiched between a drug impermeable 
backing laminate and a rate controlling polymeric membrane. The drug molecules are 
permitted to release only through the rate controlling polymeric membrane.  
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In the drug reservoir compartment the drug solids are dispersed homogeneously 
in a solid polymer matrix (e.g., poly isobutylene), suspended in an unleachable, viscous 
liquid medium (e.g., silicone fluid) to form a pase like suspension, or dissolved in a 
releasable solvent (e.g.,alkyl alcohol) to form a clear drug solution. On the external 
surface of the polymeric membrane a thin layer of drug compatible, hypoallergenic 
pressure sensitive adhesive polymer (e.g., silicone adhesive) may be applied to provide 
intimate contact of the TDDS with the skin surface. The intrinsic rate of drug release 
from this type of TDDS is defined by: 
dt
dQ =
m22/m2mm/r
m2l/rm/r
hDKhDK
DDKK
+ Cr ------------------------Æ (5) 
Where: C R – Drug concentration in the reservoir compartment. 
Km/r& Ka/m  -- Are the partition coefficients for the interfacial partitioning of drug from 
the reservoir to the membrane and from the membrane to the adhesive. 
Dm& D2  --- Are the diffusion coefficients in the rate-controlling membrane and in the 
adhesive layer. 
hm& ha  -- are the thickness of rate-controlling membrane and adhesive layer. 
II. Polymer matrix Diffusion-Controlled TDDS: 
 
In this approach the drug reservoir is formed by homogeneously dispersing the 
drug solid in a hydrophilic or lipophilic polymer matrix and the medicated polymer 
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solubility in a lipophilic polymer by high shear mechanical force to form thousands of 
unleachable microscopic drug reservoirs.  This thermodynamically unstable dispersion 
is quickly stabilized by immediately cross linking the polymer chains in-situ, which 
produces a medicated polymer disk with a constant surface area and a fixed thickness. 
The rate of drug release from a microreservoir drug delivery system is defined by:  
=
dt
dQ
)7(11)1(
mm1
11
p
222dp
2rp >−−−−−−−−−−−⎥⎦
⎤⎢⎣
⎡
⎟⎟⎠
⎞
⎜⎜⎝
⎛ +−−+ kkh
BSDBS
AKhDhD
AKDD
 
Where: 
A = a/b, a is the ratio of the drug concentration in the bulk of elution solution 
over the drug solubility in the same medium, and b is the ratio of the drug concentration 
at the outer edge of the polymer coating membrane over the drug solubility in the same 
polymer composition. 
B = is the ratio of the drug concentration at the inner edge of the interfacial 
barrier over the drug solubility in the polymer matrix. 
Kl, Km & Kp = are the partition co-efficients for the interfacial partitioning of 
drug from the liquid compartment to the polymer matrix, from the polymer matrix to 
the polymer coating membrane, and from the polymer coating membrane to the elution 
solution (or skin). 
Dl, Dp & Ds – are the drug diffusivities in the liquid compartment, polymer 
coating membrane, and elution solution (or skin), respectively. 
Sl & Sp – are the solubilities of the drug in the liquid compartment and in the 
polymer matrix, respectively and hl, hp & hd – are the thickness of the liquid layer 
surrounding the drug particles, the polymer coating membrane around the polymer 
matrix, and the hydrodynamic diffusion layer surrounding the polymer coating 
membrane, respectively. 
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1.8 Use of Transdermal Patch 
   
                                                      Fig No.8: Use of Transdermal Patch 
 
It is important to use a different application site every day to avoid skin 
irritationSuggested rotation is : 
Day 1  - Upper right arm 
Day 2  - Upper right chest 
Day 3  - Upper left chest 
Day 4  - Upper left arm, 
Then repeat from day 1. 
1.8.1. Transdermal Patches Available in the Market13 
 Nowadays, the transdermal route has become one of the most successful and 
innovative focus for research in drug delivery with around 40% of the drug candidate 
being under clinical evaluation related to transdermal or dermal systems.  
 The market for transdermal product has been in a significant upward trend and 
this is likely to continue to deliver real therapeutic benefit to patients around the world. 
More than 35 TDDS products have now been approved for sale in the US, and 
approximately 16 active ingredients have been approved for use globally. 
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  Statistics reveal a market of $ 12.7 billion in the year 2005 that is expected to 
increase to $ 21.5 billion in the year 2010 and $ 31.5 billion in the year 2015. The pie 
diagram shows the global transdermal product sales. 
 
 
Fig No. 9: Pie diagram of popularly marketed Transdermal patch 
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Table No .1: List  of  Transdermal  Patches  available  in The  Market          
Brand Name Drug Manufacturer Indications 
NicotinellR Nicotine Novartis Pharmacological 
smoking cessation 
MatrifenR Fentanyl Nycomed Pain relief patch 
NeuproR Rigotine UCB and 
Schwarx 
pharma 
Early-state idiopathic 
parkinson’s disease 
Alora Estradiol Thera Tech/ 
Procter and 
gamble 
Postmenstrual 
syndrome 
Nitrodisc Nitroglycerin Robert’s 
Pharmaceuticals
Angina pectoris 
Nuvelle TS Estrogen/ 
Progesterone 
Ethical 
Holdings/ 
Schering 
Hormone replacement 
therapy 
Testoderm TTSR Testosterone Alza Hypogonadism in 
males 
OxytrolR Oxybutynin Watson Pharma Overactive bladder 
Catapres TTSR Clonidine Alza/Boehinger 
Ingelheim 
Hypertension 
Minitran Nitroglycerin 3M 
Pharmaceuticals
Angina pectoris 
Duragesic Fentanyl Alza/Jannssen 
Pharmaceutical 
Moderate/ severe pain 
Emsam Selegiline Bristol-Myers 
Squibb 
Major depressive 
disorder 
Neupro Rotigotine Schwarz 
Pharma 
Parkinson’s Disease 
INTRODUCTION 
 
33 
 
Exelon Rivastigmine Novartis Dementia 
Daytrana Methylphenidate Shire Attention deficit 
hyperactivity disorder 
Synera Lidocaine/ 
tetracaine 
Endo 
Pharmaceuticals
Local dermal 
Analgesia 
Ionsys Fentanyl HCI 
(iontophoresis) 
Alza Acute postoperative 
pain 
Scnoprep Lidocaine 
(ultrasound) 
Echo 
Therapeutics 
Local dermal 
Anesthesia 
Oxytrol Oxybutynin Watson Pharma Overactive Bladder 
Climara Pro Estradiol Bayer 
Healthcare 
Pharmaceuticals
Menopausal 
symptoms 
Ortho Evra Ethinyl estradiol/ 
norelgestromin 
Ortho-Mc Neil 
Pharmaceutical 
Contraception 
Nicoderm,Habitrol,Proste
p 
Nicotine Glaxo Smith 
Kline, Novartis 
Consumer 
Health, Elan 
Smoking cessation 
Testoderm Testosterone Alza Testosterone 
Deficiency 
Iontocaine Lidocaine/ 
epinephrine 
(iontophoresis) 
Iomed Local dermal 
Analgesia 
Combipatch Estradiol/ 
norethidrone 
Novartis Menopausal 
symptoms 
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1.9 . Therapeutic Applications of TDDS13 
¾ Hisetal, used in treatment of multiple sclerosis can be formulated in TDDS 
using oleic acid as permeation enhancer to achieve sufficient drug delivery. 
¾ Diclofenac sodium, Celecoxib used as NSAID’s, formulated in TDDS can 
overcome gastric lesions associated with oral dose. 
¾ Drugs used for long term dosing in chronic diseases like captopril, verapamil, 
terbutaline sulphate, pinacidil, propranolol which have short biological half 
life, considerable first pass metabolism can be formulated as TDDS to achieve 
prolonged steady state plasma concentration. 
¾ Gel formulation with lipid disperse system of betahistine has potential for 
development of an efficient controlled release transdermal system. 
¾ Enhancer and co-solvent can synergictically enhance the delivery of peptides 
like thyrotropin releasing hormone across human skin. 
¾ Prazosin HCL in membrane controlled TDDS can deliver drug enough to 
maintain minimum effective concentration and can avoid hypotension 
associated with high initial oral dosing. 
¾ TDDS of indomethacin in polyvinylpyrolidone polymer (acting as anti 
nucleating agent) can provide better anti-inflammatory activity and lower ulcer 
indices compared to oral administration. 
¾ Diclofenac sodium, existing in anionic form at skin pH can be formulated as 
ion- pairs with oppositely charged enhancers to enhance transdermal delivery 
compared to non-ion paired forms. 
¾ Iontophoresis can increase permeation rate of hydrophilic atenolol to a greater 
extent than permeation enhancer and overcome incomplete absorption on GIT. 
¾ Nimesulide in sodium alginate transdermal gel can provide better analgesic 
and anti-inflammatory activity and avoid adverse effects associated with long 
term treatment with high oral dose. 
¾ Terbutaline sulphate, being dia magnetic can be incorporated in magnetic 
TDDS to experience driving force to escape from applied magnetic field and 
enhance diffusion across the skin. 
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¾ Bupropion HCl, an antidepressant drug can be converted to free base to 
increase lipophilicity and transdermal delivery and avoid release of fatal 
metabolites associated with oral dosing. 
¾ Zidovudine, an anti-HIV drug, formulated in TDDS and overcome toxic 
effects associated with frequent higher oral dose. 
¾ Levonorgestrel, a potent contraceptive agent, formulated as transdermal 
protransferosome gel can provide enhanced, prolonged and controlled delivery 
and overcome GI disturbances, weight gain, irregular bleeding, headache etc. 
associated with oral dosing. 
¾ Polymerized rosin can be used ti design matrix type TDDS of Diltiazem HCl 
to prolong drugrelease and avoid variable and extensive first pass metabolism 
on oral dose. 
¾ Ester prodrug of ketorolac can provide enhanced permeation whereas 
nanostructured lipid carrier can act as controlled release system and avoid 
gastric ulceration and renal failure associated with frequent long term oral 
dosing. 
1.10. Limitations of Transdermal Delivery System 
¾ Higher molecular weight candidates (>500Daltons) fail to penetrate the 
Stratum corneum. 
¾ Drugs with very low or high partition coefficient fail to reach systemic 
circulation. 
¾ High melting drugs are not suitable due to their low solubility both in water 
and fat. 
¾ Possibility of local irritation at the site of patch application. 
¾ A lag time associated with the  delivery of the drug across the  skin, resulting 
in a delay in onset of action. 
¾ Variation of absorption rate based on site of application. 
¾ Presence of skin diseases. 
¾ Variation in adhesive effectiveness in different individuals. 
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1.11. Evaluation of Transdermal Patches 14 
Development  of controlled release transdermal dosage form is a complex 
process involving extensive research. Transdermal patches have been developed to 
improve clinical efficacy of the drug and to enhance patient compliance by delivering 
smaller amount of drug at a predetermined rate. This makes evaluation studies even 
more important in order to ensure their desired performance and reproducibility under 
the specified environmental conditions. 
These studies are predictive of transdermal dosage forms and can be classified into 
following types. 
I. Physicochemical evaluation 
II. In-vitro evaluation 
III. Ex-vivo evaluation. 
Upon the success of physicochemical and in-vitro studies, in-vivo evaluations may 
be conducted. 
I. Physicochemical Evaluation: 
1. Thickness: The thickness of transdermal film is determined by screw gauge at 
different points of the film.15 
2. Unformity of weight: Weight variation is studied by individually weighing 10 
randomly selected patcvhes and calculating the average weight. The individual 
weight should not deviate significantly from the average weight.16 
3. Drug content determination: An accurately weighed portion of film (about 
100 mg) is dissolved in 100 ml. of suitable solvent in which drug is soluble and 
then the solution is shaken continuously for 24 h in shaker incubator. Then the 
whole solution is sonicated. After sonication and subsequent filtration, drug in 
solution is estimated spectrophotometrically by appropriate dilution.17 
4. Content uniformity test: 10 patches are selected and content is determined for 
individual patches. If 9 out of 10 patches have content between 85% to 115% of 
the specified value and one has content not less than 75% to 125% of the 
specified value, then transdermal patches pass the test of content uniformity. 
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 But if 3 patches have content in the range of 75% to 125%, then additional 20 
patches are tested for drug content. If these 20 patches have range from 85% to 
115% then the transdermal patches pass the test. 
5. Moisture content: The prepared films are weighed individually and kept in a 
desiccators containing calcium chloride at room temperature for 24 h. The films 
are weighed again after a specified interval until they show a constant weight. 
Percent moisture content is calculated using following formula.18 
% Moisture content = Initial weight – Final weight X 100 
        Final weight 
6. Moisture Uptake: Weighed films are kept in a desiccator at room temperature 
for 24 h. These are then taken out and exposed to 84% relative humidity using 
saturated solution of potassium chloride in a desiccator until a constant weight is 
achieved. Percent moisture uptake is calculated as given below.18 
 
% moisture uptake = Final weight – Initial weight X 100 
    Initial weight 
7. Folding Endurance: Evaluation of folding endurance involves determining the 
folding capacity of the films subjected to frequent extreme conditions of folding. 
Folding endurance is determined by repeatedly folding the film at the same 
place until it break; the number of times the films could be folded at the same 
place without breaking is folding endurance value.18 
8. Tensile Strength: To determine tensile strength, polymeric films are 
sandwiched separately by corked linear iron plates. One end of the films is kept 
fixed with the help of an iron screen and other end is connected to a freely 
movable thread over a pulley. The weights are added gradually to the pan 
attached with the hanging end of the thread. A pointer on the thread is used to 
measure the elongation of the film. The weight just sufficient to break the film is 
noted. The tensile strength can be calculated using the following equation.20 
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Tensile strength = F/a.b(1=L/1) 
 F is the force required to break; a is width of film; b is thickness of film; 
L is length of  film; 1 is elongation of film at break point. 
II. The in-vitro evaluation 5,6 
The objective of in-vitro research is often to find correlation between laboratory 
results and the transdermal absorption experienced by living subjects, so that, in-vivo 
experimentation may be curtailed. 
The factors to be considered while selecting an in-vitro system include: 
1. The rate limiting process: drug solubization or diffusion in the vehicle, 
partitioning from the vehicle, diffusion through the test membrane or 
partitioning and removal by the receptor phase. 
2. The intrinsic diffusivity of the permanent and apparent diffusivity. 
3. The predominating route of diffusion during the experiment and the relative 
extents of drug binding the metyabolism, occurring in the membrane, delivery 
and receptor phases. 
4. The intrinsic barrier potential of the membrane and the effects that vehicle 
components may have on its retardative properties. Hydration of the membrane 
and the presence of penetration enhancers may be important here. Inter-
specimen variability between membranes of the same type may markedly 
influence experimental results. 
The various types of cells lused for carrying out in-vitro release studies are 
1. Chien and Vilia cell 
2. Franz diffusion cell 
3. Keshary-chien diffusion cell 
4. USP XXIII’s ge berak drug release standards for TDDS. 
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Usually Diffusion Cell Design contains two parts donor and received 
compartment: 
All materials should be assessed for their ability to absorb or adsorb the test 
penetrant. 
1. Donor Compartment is designed in such a way to achieve 
 Easy access to deliver the penetrants to the skin. 
 (37±1o)c of temperature. 
 Control of evaporation for volatile vehicles and penetrants. 
           Membrane used in study should have following characteristics: 
 For the study of penetration kinetics, only porcine epithelium should be 
used. 
 For vehicle/device release studies, other barriers may be used. 
 The skin sample should ideally contain only SC. 
 A molecule of known penetration kinetics should be used prior to the test 
molecule, to assess barrier function. 
 Wherever applicable, metabolic viability of epidermis must be assessed. 
2. Receptor Compartment 
 Either, flow-through or static. 
 (37±1o)c of temperature 
 Sufficient volume to maintain infinite sink conditions. 
 Stirred without obvious formation of boundary layers. 
3. Receptor Fluid 
 Should not compromise barrier function. 
 Should be of favorable partitioning characteristics to receive the 
penetrant. 
 Capable of maintaining epidermal viability wherever necessary. 
 Must be contained once collected. 
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1.12.1 . Clinical features       
  Scabies manifests in two main ways: People infected with classical 
scabies will present with intense itchiness which is more severe at night or after a bath. 
 The common affected areas are finger webs and skin folds of wrists, elbows, armpits, 
nipples, lower abdomen, external genitalia, buttocks and groins.  Rashes, thread-like 
lesions or vesicles may be seen on the skin.  The face and scalp are usually spared, 
except in infants, young children and immune-compromised persons. 
A rare but severe type of scabies known as Norwegian or crusted scabies can 
occur in institutionalized people, particularly in those who are weak or mentally 
disabled.   The skin lesions appear as marked scales and crusts.  The nails may thicken, 
with debris in the nail bed.  Face and scalp can also be affected.  This type of scabies is 
highly contagious because an infected person may harbour thousands of mites, 
compared with 10-15 mites present in classical scabies. 
1.12.2. Path physiologys of Scabies22       
• Mode of transmission       
 Scabies usually spreads through direct skin contact with the infested 
people.  Their clothing and bedding may also carry the mites/eggs and transmit 
the disease. Transmission within household and institutional setting is common. 
• Incubation period       
 Incubation period is about 2-6 weeks for people without previous 
exposure to the disease.  For people who have previously been infested with 
scabies, symptoms develop earlier, usually within 1-4 days after re-exposure. 
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    S. Scabiei Stratum  
              
   A      B 
Fig No.11:A. Adult female S. scabiae, ventral (stomach) view, with internal egg 
           B. Adult scabies mite (cross-section) in outer layer of skin  
    (Stratum  corneum)  
 
• Management 
•  If you suspect scabies, seek medical advice immediately 
•  Apply topical medicated lotions and take drugs according to the doctor’s advice 
to kill the mites and control itchiness respectively 
•  Family member(s) and sexual partner(s) of the infested persons should also seek 
medical advice and receive treatment if necessary 
•  When caring for and coming into contact with the infested persons, were   
appropriate personal protective gear such as gloves and apron   
•  Wash hands thoroughly before and after contact with the infested person 
•  Wash the clothing, towels and bed linen of the infested persons separately. 
These items should be washed in hot water at 60°C or above, for not less than 10 
minutes so as to kill the mite and its eggs.  Clean equipment for shared use with 
detergent before using on other persons.  Place non-washable items in a plastic 
bag and seal up for at least 14 days before reuse 
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1.12.3. Prevention 
•  Keep good personal hygiene, wash hands and body frequently 
•  Regularly change into clean clothing, towels and bed linen 
•  Avoid sharing clothing and personal items with others 
•  Perform skin inspection for institutionalized residents regularly for early 
identification of infestation 
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                                           2. LITERATURE SURVEY 
2.1. Literature Review of  TDDS : 
¾ Santhosh K et al., 2013  Formulated and Evaluated Ketoprofen Transdermal 
Patches.They concluded that the 4:1 ratio formulation using ethyl cellulose 
and PVP showed best drug release (97.87%) in 24 hrs23 
 
¾ Vennadeepthi et al., 2013  Formulated and Evaluated Transdermal Patch of 
Anti hypertensive drug(Atenolol). They concluded that the F4 formulation 
prepared by using HPMC: Eudragit RL 100(4:3 ratio) showed  controlled 
release up to 24 hrs24 
 
¾ SwethaVennapossa et al., 2013  Formulated and Evaluated Matrix type 
Tran sdermal Patch containing Rivastigmine Tartarate. They concluded that 
the in-vitro drug release studies revealed that the formulation F3 provided 
sustained release due to increase in amount of EC in the formulation.  More 
or less similar trend was studied in case of F2 and F1 formulations. When 
the average rate constant of these 3 formulations were compared it was 
found that F3(PVP:EC-1:5) had the slowest release rate of all the 
formulations studied. Therefore based on the above observations it can be 
reasonably concluded that PVP-EC (1:5) polymers are better over PVP-EC 
(1:1&1:3) for the development of TDDS of Rivastigmine Tartarate25 
 
¾ Kansagra Hemanh et al., 2012 Formulated and Evaluated Transdermal 
Patch of  Sertaconazole nitrate. The permeation studies illustrated that the 
ratio of polyvinyl pyrrolidone and ethyl cellulose 1:5 showed good 
controlled release. Higuchi and Korsmeyer-Peppas models were used for 
optimizing the formulation26 
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¾ Kunal N Patel  et al., 2012  Formulated and Evaluated Transdermal Patches 
of Diclofenacacid. The prepared patches showed good uniformity with 
regard to drug content and drug release. Formulation F3 has achieved the 
targets of study such as extended release, avoidance of first pass metabolism, 
reduced frequency of administration and thus may improve the patient 
compliance27 
 
¾ G. Parthasarathy et al., 2011 Designed, Formulated and Evaluated 
Transdermal drug Patches of Naproxen with various polymers. The study 
showed that the ethylcellulose and Hydroxy propyl methyl cellulose along 
with the plasticizer dibutylphthalate 10% w/v of polymer weight was 
suitable for good flexibility and elasticity28 
 
¾ Sarswathi R et al., 2010  Formulated and Evaluated Transdermal Patches of 
Curcumin.The in - vitro permeation studies of patches was carried out using 
0.5% Sodium Lauryl Sulphatesolution in the receptor compartment with 
their different patches, F1, F2 and F3 using HPMC and EC bring the 
satisfactory release of curcumin. The cumulative percentage drug release of 
patch F1-82.20%, F2-74.06% and F3-68.27%. The release kinetics was 
evaluated making by use of Zero order, first order, Higuchi’s diffusion and 
Korsemeyer-Peppas equation. The drug release through transdermal patches 
of curcumin followed Zero order kinetics29 
 
¾ Rakesh .P. Patelet al., 2009 Formulated and Evaluated Transdermal Patch 
of Aceclofenac. The study indicated that as the drug permeation increased 
with increased concentration of penetration enhancer30 
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               2.2. Literature Review of   Scabies: 
¾ Johnston G et al.,(2011) reviewed the diagnosis and treatment of Scabies 19 
 
¾ Chosidow O, (2006) reviewed the clinical practices of Scabies20 
 
¾ Stanley scheindlin et al., (2004) discussed transdermal drug delivery: past, 
present and future scope in molecular interventions21, 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE SURVEY 
 
47 
 
2.3. Literature Review of Acalypha indica Linn. 
• Jagatheeswari et al., (2013) carried out a review of its traditional uses and 
pharmacological properties. Medicinal herbs are moving from fringe to 
mainstream use with a greater number of people seeking remedies and health 
approaches free from side effects caused by synthetic chemicals. India officially 
recognizes over 3000 plants for their medicinal value. It is generally estimated 
that over 6000 plants in India are in use in traditional, folk and herbal medicine. 
This article aims to provide a comprehensive review on the and pharmacological 
aspects of Acalypha indica  Linn.31 
 
• Siva et al., (2009) carried out the study on four different extracts of whole plant 
of Acalypha indica Linn. . They tested for post-coital anti fertility activity in 
female albino rats. Of these, only pet.ether and ethanol extracts were found most 
significant activity. But activity is reversible on withdrawal of extract32 
 
• Siddique et al., (2008) carried out the aqueous extract of Acalypha indica Linn. 
were studied for Neuro - protection and neuro-therapy effect ex-vivo on 
musculus gastro frog studies were done on two groups of frog, the parameters 
measured in this study are electrical activities such as amount and duration (in 
second) of repolarization, depolarization, resting potential, and height of spike 
after electrical stimulation. Extract showed both activities33 
 
• M.Karthikeyan et al., (2008)  Extracts of leaves of Acalypha indica Linn. was 
evaluated for antibacterial activity against both gram positive and gram-negative 
bacteria. All extracts shown activity against various strains of gram positive and 
in gram negative only on Pseudomonas aeruginosa34 
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• Dibinlal et al., (2008)  Fresh juice of  Acalipha indica Linn. leaf were evaluated 
for anti-inflammatory activity on four groups of albino rats which are pretreated 
orally with control, standard, (indomethacin), in combination of  both    
Acalypha indica Linn. & Indomethacin, Acalypha indica Linn. juice was 
effective in inhibition of paw volume and oedema34 
 
• Kannan  et al., (2008)  carried out  the different  leaf extract of  Acalypha 
indica Linn. tested for larvicidal  against Anapheles stephensi. the ability of 
ovicidal activity was observed, the percent  was versely proporitional to 
concentration of extract and directly proportional to the eggs. Result of extracts 
having promising activity35 
• Rajeshwari et al., (2007) synthesized nanoparticles using leaf extract of 
Acalypha indica Linn. The antibacterial activity of synthesized silver 
nanoparticles showed effective inhibitory activity against water borne pathogens 
Viz., Escherichia coli and Vibrio cholerae36 
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3.AIM AND OBJECTIVE 
 
3.1. Aim 
 
   To prepare transdermal  patch of  Methanolic Extract of Acalypha  indica  Linn. 
using  different polymers for the treatment of scabies. 
 
3.2. Objective 
• To formulate the herbal extract into a novel dosage form 
 
• To prepare Transdermal patch of Methanolic Extract of Acalypha indica 
Linn.using different  polymers and to evaluate its effective release to 
treat scabies 
 
• To provide a direct entry of drug into the systemic circulation to give 
immediate relief  and to give sustained action 
 
 The Transdermal route is easily accessible for self-medication andsafe, hence 
it is well accepted by patients. Since the device can be easily adhered on to the skin 
and removed from the site of application. 
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4. PLAN OF THE WORK 
 Literature Survey 
 Selection of Herb 
 Collection of leaves of Acalypha indica  Linn. 
 Authentication 
 Extraction (Soxylation method) 
 Phytochemical evaluations 
 Trial batches for Transdermal patches (extract : polymer in different ratio) 
 Evaluations 
1) Physico chemical evaluation 
9 Percent moisture absorption 
9 Percent moisture loss 
9 Thickness  
9 Weight variation 
9 Folding endurance 
9 Surface pH 
9 Drug content 
2) In- vitro Evaluation 
 Stability studies  
 Anti-Microbial  studies 
 Ex-vivo studies  
 Release kinetics  
 Results and discussions  
 Summary and Conclusion  
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5. PLANT DESCRIPTION 
  
Fig  No.12: Leaves of Acalypha indica Linn. 
5.1.1 Acalypha indica Linn.37 
Kingdom  :  Plantae 
Order   : Malpighiales 
Family  : Euphorbiaceae 
Genus   :  Acalypha 
Species   : indica 
Common Nam : Acalypha indica Linn. 
English  :  Indian acalypha, Indian nettle, three-seeded mercury 
Tamil   :  Poonamayakki, Kuppaimeni 
Sanskrit  : Harita-manjari 
Parts Used  : Leaf 
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5.1.2.Description 
Colour  : Green  
Taste   :  Bitter 
Odour   : Pungent 
Solubility  : Methanol 
5.1.3.Distribution 
India, Africa, Oceania, and South East Asia 
5.1.4.Habitat 
Common annual shrub in Indian gardens, backyards of houses and waste place 
throughout the plains of India 
5.1.5.Vernacular names of Acalypha indica Linn. 
English : Indian Acalypha 
Kannada : Chalmari 
Malayalam : Kupameni  
Others : Rudra, kuppu, khokali 
Tamil  : Kuppaimeni, naaikurungu, poonamayakki 
5.1.6. Chemical constituents 
9 Acalyphamide 
9 Acalyphin 
9 Acalyphamide acetate 
9 Alkaloid 
9 Catachols 
9 Flavonoids 
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5.1.8.Traditional uses 
9 Anti-inflammatory, analgesic, irritations, stabbing pain, wheezing 
9 Anti-tuberculosis, burns 
9 For removing the toxin arising out of Rat bite 
9 Mixed with garlic they are used as Anthelmintic in worms 
9 Mixed with garlic they are applied to scabies (MateriaMedica (Vegetable 
section), Volume I, by Dr. MurugesaMuthaliar, pages: 359, publisher, 
Tamilnadu Siddha Medical Council, Chennai. Fourth edition 1988.) 
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5.2.2. Sources of Pectin 
• Apples – 1 to 1.5% 
• Apricot – 1% 
• Cherries – 0.4% 
• Oranges – 0.5 to 3.5% 
• Carrots approx – 1.4% 
• Citrus peels – 53% 
5.2.3. General properties of Pectin 
 Pectin is a natural polymer. Pectin is soluble in pure water. Monovalent 
cation (alkali metal) salts of pectinic and pectic acids are usually soluble in water, 
di- and trivalent cations salts are weakly soluble or insoluble. Dry powdered pectin, 
when added to water, has tendency to hydrate very rapidly, forming clumps. These 
crumps consist of semi dry packets of pectin contained in an envelope of highly 
hydrated outer coating. Further solubilisation of such cramps is very slow. Dilute 
pectin solutions are Newtonian but a moderate concentration, they exhibit the non-
Newtonian, pseudoplasticbehaviourcharacterstics. As with solubility, the viscosity 
of a pectin solution is related to the molecular weight, concentration of the 
preparation, and the pH and presence of counter ions in the solution. Viscosity, 
solubility and gelation are generally related. For example, factors that increase gel 
strength will increase the tendency to gel, decrease solubility, and increase viscosity, 
and vice versa. 
5.2.4. Pharmaceutical uses of pectin 
9 Pectin has applications in the pharmaceutical industry. Pectin favorably 
influences cholesterol levels in blood. Consumption of at least 6g/day of 
pectin is necessary to have a significant effect in cholesterol reduction. 
9 Pectin acts as a natural prophylactic substance against poisoning with 
toxications. It has been shown to effective in removing lead and mercury 
from the gastrointestinal tract and respiratory organs. 
9 Pectin injected intravenously, shortens the coagulation time of drawn blood, 
thus being useful in controlling hemorrhage or local bleeding. 
EXCIPIENT PROFILE 
 
58 
 
9 Pectin and combinations of pectin with other colloids have been used 
extensively to treat diarrheal diseases, especially in infants and children. 
9 Pectin reduces rate of digestion by immobilizing food components in the 
intestine. This results in less absorption of food. 
9 Pectin hydrogels have been used in tablet formulations as a binding agent 
matrix tablet formulations. HM-pectin’s for their potential value in 
controlled release matrix formulations. The application of a binary polymer 
system, (i.e) HM-pectin and hydroxypropyl methylcellulose. 
9 Pectin beads prepared by the ionotropic gelation method were used as a 
sustained release drug delivery system. 
9 Pectin has a promising pharmaceutical uses and is presently considered as a 
carrier material in colon-specific drug delivery systems ( for systemic action 
or a topical treatment of diseases such as ulcerative colitis, crohn’s disease, 
colon carcinomas) 
9 Pectin is an interesting candidate for pharmaceutical use, e.g. as a carrier of 
variety of drugs for controlled release applications. Many techniques have 
been used to manufacture the pectin-based delivery systems, especially 
ionotropic gelation and gel coating. 
5.3. Sodium alginate:40 
Nonproprietary Names: 
 BP  :  Sodium alginate 
 PhEur  : Natriialginas 
USPNF : Sodium alginate 
Synonyms 
 Algin; alginic acid, sodium salt; E401; Kelcosol; Keltone; Protanal; sodium 
polymannuronate 
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The adhesiveness of hydrogels prepared from sodium alginate has been 
investigated and drug releases from oral mucosal adhesive tablets, and buccal gels, 
based on sodium alginate have been reported. Other novel delivery systems 
containing sodium alginate include ophthalmic solutions that form a gel in-situ when 
administered to the eye; and in- situ forming gel containing paracetamol fororal 
administration; and a freeze-dried device intended for the delivery of bone-growth 
factors Hydrogel systems containing alginates have also been investigated for 
delivery of proteins and peptides.  
 
Therapeutically, sodium alginate has been used in combination with an      
H2-receptor antagonist in the management of gastro esophageal reflux, and as a 
haemostatic agent in surgical dressings. Alginate dressings, used to treat exuding 
wounds, often contain significant amounts of sodium alginate as this improves the 
gelling properties. Sponges composed of sodium alginate and chitosan produce a 
sustained drug release and may be useful as wound dressings or as tissue 
engineering matrices. Sodium alginate is also used in cosmetics and food products. 
 
5.3.5. Description 
 Sodium alginate occurs as an odorless and tasteless, white to pale yellowish-
brown coloured powder. 
5.3.6. Typical Properties 
 Acidity/alkalinity: pH 7.2 for a 1% w/v aqueous solution. 
 
Solubility 
 Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water 
mixtures in which the ethanol content is greater than 30%. Also, practically 
insoluble in other organic solvents and aqueous acidic solutions in which the pH is 
less than 7. Slowly soluble in water, forming a viscous colloidal solution. 
 
Viscosity (dynamic) 
 Various grades of sodium alginate are commercially available that yield 
aqueous solutions of varying viscosity. Typically, a 1% w/v aqueous solution, at 
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200C, will have a viscosity of 20-400 m Pas (20-400cP). Viscosity may vary 
depending upon concentration, pH, temperature, or the presence of metal ions. 
Above pH 10, viscosity decreases. 
 
5.3.7. Stability and Storage Conditions 
 Sodium alginate is a hygroscopic material, although it is stable if stored at 
low relative humidities and a cool temperature. 
 
 Aqueous solutions of sodium alginate are most stable at pH 4-10. Below    
pH 3, alginic acid is precipitated. A 1% w/v aqueous solution of sodium alginate 
exposed to differing temperatures had a viscosity 60-80% of its original value after 
storage for 2 years. Solutions should not be stored in metal containers. 
 
 Sodium alginate solutions are susceptible on storage to microbial spoilage, 
which may affect solution viscosity. Solutions are ideally sterilized using ethylene 
oxide, although filtration using a 0.45µm filter also has only a slight adverse effect 
on solution viscosity.  Heating sodium alginate solutions to temperatures above 700C 
causes depolymerization with a subsequent loss of viscosity. Autoclaving of 
solutions can cause a decrease in viscosity, which may vary depending upon the 
nature of any other substances present. Gamma irradiation should not be used to 
sterilize sodium alginate solutions since this process severely reduces solution 
viscosity. 
 Preparations for external use may be preserved by the addition of 0.1% 
chlorcresol, 0.1% chloroxylenol or parabens. If the medium is acidic, benzoic acid 
may also be used. The bulk material should be stored in an airtight container in a 
cool, dry place. 
Incompatibilities 
 Sodium alginate is incompatible with acridine derivatives, crystal violet, 
phenyl mercuric acetate and nitrate, calcium salts, heavy metals, and ethanol in 
concentrations greater than 5%. Low concentrations of electrolytes cause an increase 
in viscosity but high electrolyte concentrations cause salting-out of sodium alginate;  
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Safety 
 Sodium alginate is widely used in cosmetics, food products, and 
pharmaceutical formulations, such as tablets and topical products, including wound 
dressings. It is generally regarded as a nontoxic and non irritant material, although 
excessive oral consumption may be harmful. A study in five healthy male volunteers 
fed a daily intake of 175 mg/kg body-weight of sodium alginate for 7 days, followed 
by a daily intake of 200 mg/kg body-weight of sodium alginate for a further 16 days, 
showed no significant adverse effects. 
 The WHO has not specified an acceptable daily intake for alginic acid and 
alginate salts as the levels used in food do not represent a hazard to health. 
 Inhalation of alginate dust may be irritant and has been associated with 
industrial-related asthma in workers involved in alginate production. However, it 
appears that the cases of asthma were linked to exposure to seaweed dust rather than 
pure alginate dust. 
Handling Precautions 
 Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Sodium alginate may be irritant to the eyes or respiratory system if 
inhaled as dust. So Eye protection, gloves and a dust respirator are recommended. 
Sodium alginate should be inhaled in a well-ventilated environment. 
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5.4.6. Solubility   : HPMC can be soluble in water and  
some organic solvents, as the right 
proportion of ethanol/water,                                              
propy alcohol/water,  
ethylene dichloride, etc. 
5.4.7. Pharmacopoeial Specifications 
Specific gravity   : 1.26-1.31 
pH     : 6.0-8.0 
 
5.4.8. Pharmaceutical Application   
¾ Film former in tablet film coating.  
¾ Lower viscosity grades are used in aqueous film coating and higher viscosity 
grades are used in solvent film coating.  
¾ High viscosity grades are used to retard the release of water soluble drugs.  
¾ Thickening agent added to vehicles for eye drops and artificial tear solutions 
at 0.45-1.0% concentrations.  
¾ Protective colloid which prevents droplets and particles from coalescing or 
agglomerating, thus inhibiting the formation of sediments, emulsifier, 
suspending agent and stabilizer in gels and ointments.  
¾ Adhesive in plastic bandages.  
 
5.4.9. Safety 
 
Human and animal feeding studies have shown hydroxyl propyl methyl 
 cellulose to be safe.  
 
5.4.10. Stability and storage  
 
Very stable in dry conditions. Solutions are stable at pH 3 - 11. Store in a 
 tight container, in a cool place. 
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5.5.Glycerin 
5.5.1.Nonproprietary Names 
BP :  Glycerol. 
PhEur :  Glycerolum. 
5.5.2. Synonyms 
Croderol; E422; glycerine; Glycon G-100; Kemstrene; Optim; 
Pricerine; 1,2,3- propanetriol; trihydroxypropane glycerol. 
 
5.5.3. Chemical name 
Propane 1, 2, 3-triol. 
5.5.4. Empirical Formula 
C3H8O3 
5.5.5.Molecular Weight 
92.09 
 
5.5.6. Structural Formuula 
 
 
HO OH 
OH 
 
GLYCEROL 
 
 
5.5.7. Description 
Itis a clear, colorless, odourless, viscous, hygroscopic liquid, it has a sweet 
taste, approximately 0.6times as sweet as sucrose. 
 
5.5.8. Functional category 
Antimicrobialpreservative,emollient,humectant,plasticizer,solvent. 
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5.5.9.Typical properties: 
• Melting point :  17.80c 
• Solubility  : soluble in water,methanol 
•   
5.5.10.Applications in Pharmaceutical Technology: 
It is used in a wide variety of pharmaceutical formulations including oral, 
otic, ophthalmic, topical & parenteral preparations. In topical pharmaceutical            
formulations and cosmetics, it is used primarily for its humectant & emollient 
properties. Inparenteral formulations it is used mainly as a solvent. In oral solutions, 
glycer in is used a solvent, sweetening agent, antimicrobial preservative and 
viscosity increasing agent. It is also used as a plasticizer and in film coatings. It is 
additionally used in topical formulation such as creams and emulsions. It is used as 
a plasticizer of gelatin in the production of soft-gelatin capsules and gelatin 
suppositories. It is employed as a therapeutic agent in a variety of clinical 
applications, and is also used as a food additive. 
 
5.5.11.Stability and Storage 
Conditions: 
It is hygroscopic.  Pure glycerinis not proneto oxidation bythe atmosphere 
under ordinary storage conditions but it decomposes on heating, with the evalution 
of toxic acrolein. Mixture of glycerin with water, ethanol & propyleneglycol are 
chemically stable.It may crystallize if stored at low temperatures; the crystals do not 
melt until warmed to 20
0C
. It should be stored in an airtight container, in a cool, dry 
place. 
 
5.6. Dimethyl Sulfoxide 
 
5.6.1. Non-proprietary Names 
 
BP  :  Dimethyl sulfoxide 
PhEur :  Dimethylissulfoxidum 
USP  :  Dimethyl sulfoxide 
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5.6.2. Synonyms 
Deltan; dimexide; dimethyl sulphoxide; DMSO; Kemsol; methylsulfoxide; 
Rimso-50; sulphinyl bismethane 
 
5.6.3. Chemical Name and CAS Registry Number 
Sulfinyl bismethane [67-68-5] 
[ 
5.6.4. Empirical Formula and Molecular Weight 
C2H6OS M.W: 78.13 
 
5.6.5. Structural Formula 
 
 
 
 
 
 
 
5.6.6. Functional Category 
Penetration enhancer; solvent. 
 
5.6.7. Applications in Pharmaceutical Formulation or Technology 
Dimethyl sulfoxide is a highly polar substance that is aprotic, therefore lacking 
acidic and basic properties. It has exceptional solvent properties for both organic 
and inorganic components, which are derived from its capacity to associate with 
both ionic species and neutral molecules that are either polar orpolarizable. 
Dimethyl sulfoxide enhances the topical penetration of drugs owing to its ability to 
displace bound water from the stratum corneum; this is accompanied by the 
extraction of lipids and configurational changes of proteins.The molecular 
interactions between dimethyl sulfoxide and the stratum corneum, as a function of 
depth and time, have been described. Much of the enhancement capacity is lost if 
the solvent is diluted. Increases in drug penetration have been reported with 
dimethyl sulfoxide concentrations as low as 15%, but significant increases in 
permeability generally require concentrations higher than 60–80%. Furthermore, 
while low molecular weight substances can penetrate quickly in to the deep layers 
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of the skin, the appreciable transport of molecules with amolecular weight of more 
than 3000 is difficult. The use of dimethyl sulfoxide to improve transdermal 
delivery has been reported forcyclosporin,timolol, and a wide range of other drugs. 
Dimethyl sulfoxide has also been used in theformulation of an injection containing 
allopurinol. It has also been investigated for use in an experimental parenteral 
preparation for the treatment of liver tumors.In paint formulations of idoxuridine, 
dimethyl sulfoxide acts both as a solvent to increase drug solubility and a means of 
enabling penetration of the antiviral agent to the deeper levels of the epidermis. 
 
5.6.8. Typical Properties 
Boiling point: 
189°C 
Dielectric constant: 
48.9 at 20°C 
Solubility: 
 Miscible with water with evolution of heat; also miscible with   
ethanol(95%), ether and most organic solvents; immiscible with paraffins, 
hydrocarbons. Practically insoluble in acetone, chloroform, ethanol (95%), and 
ether. 
Vapor pressure: 
0.37 mm at 20°C 
Viscosity (dynamic): 
1.1 mPa s (1.1 cP) at 27°C 
5.6.9. Stability and Storage Conditions 
Dimethyl sulfoxide is reasonably stable to heat but upon prolonged reflux it 
decomposes slightly to methyl mercaptan and bismethylthiomethane. This 
decomposition is aided by acids, and is retarded by many bases. When heated to 
decomposition, toxic fumes are emitted.  
 
At temperatures between 40–60°C, it has been reported that dimethyl 
sulfoxide suffers a partial breakdown, which is indicated by changes in physical 
properties such as refractive index, density, and viscosity. Dimethyl sulfoxide 
should be stored in airtight, light-resistant containers.The PhEur 2005 states that 
glass containers should be used. Contact with plastics should be avoided. 
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6. MATERIALS AND METHODS 
6.1. List of Chemicals 
Table No: 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO Chemical Name Company Name 
1 SLS Merck Limited, Mumbai 
2 Pectin Loba, Mumbai 
3 Sodium alginate Kemphasol, Bombay 
4 HPMC HiMedia Laboratories Limited, 
Mumbai 
5 DMSO Merck Limited, Mumbai 
6 Glycerin Merk Limited, Mumbai 
7 Potassium 
dihydrogenortho 
phosphate 
Microfine Chemicals,  
New Delhi 
8 Sodium hydroxide Microfine Chemicals, New Delhi 
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6.2. List of Equipments 
Table No. 3: 
 
 
 
 
 
 
 
 
 
S.NO Name of Equipment Name of 
Manufacturer 
Purpose 
1 Dessicator - Moisture content 
studies 
2 Digital Verniercaliper - Patch thickness 
Studies 
3 Electronic balance Sortorius, Germany Weighing purpose 
4 Digital pH meter Elico Ltd, AP, India Surface pH study 
5 Fourier transform 
Infrared Spectrometer 
Perkin-Elmer, USA Compatibility 
studies 
6 Magnetic Stirrer ROTEK, 
W.Vengola, Kerala, 
India 
Diffusion Studies 
7 UV 
Spectrophotometer 
Shimadzu 1700, 
Japan 
Finding Absorption 
maxima 
8 Environment test 
Chamber 
Heco, Germany For stability studies 
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6.3. Preformulation Studies 
 Preformulation testing is the first step in the rational development of 
dosage forms of drugs substance. It can be defined as an investigation of physical and 
chemical properties of a drug substance alone and when combined with excipients. The 
overall objective of preformulation testing is to generate information useful to the 
formulator in developing stable and bioavailable dosage forms that can be man 
produced. 
The following Preformulation studies are carried out 
• Finding the absorption maxima 
• Physical appearance 
• Solubility 
• Melting point 
• Standard curve 
• Infrared spectroscopy studies (compatibility studies) 
6.4. Finding the absorption maxima (λ  max): 
The absorption maxima were found for identification of drug.  
Ultraviolet Visible spectrophotometry has been used to obtain specific information on 
the chromophoric part of the molecules. Organic molecules in solutions when exposed 
to light in the Visible/Ultraviolet region of the spectrum absorb light of particular 
wavelength depending on the type of electronic transition associated with the 
absorption. 
 The drug solution (5, 10, 15, 20, 25 µg/ml) in distilled water was taken 
in a standard cuvette and scanned in the range of 200-400 nm in UV spectrophotometer. 
It exhibits maxima at 260nm. Therefore, further all measurements were taken at 260nm. 
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6.5.Collection of Acalypha indica  Linn. leaves 
  Acalypha indica Linn. leaves were collected from in and around Trichy district, 
Tamilnadu. Collected leaves were authenticated by Botanist, Dept. of Botany, National 
College, Trichy. Leaves were cleaned and shade driedat room temperature.  
6.6. Extraction of leaves of Acalypha indica Linn.42 
 The shade dried leaves were subjected to size reduction and passed in to sieve 
no 20 and then 40.About 500g of the dried powder was extracted continuously in 
Soxhlet apparatus with petroleum ether for 24 hrs to remove the waxy materials. Then it 
was extracted with Methanol for 72hrs.After 72hrs, the solvent was evaporated to obtain 
the crude extract (6.5%w/v). The extract was dried under vacuum oven. 
 
                                                           Fig No.16: Soxhylation 
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6.7. Phytochemical Studies43 
The ME (Methanolic Extract) was subjected to phytochemical studies to find out 
the presence and absence of constituents. 
Table No.4:   Phytochemical Tests  
Test for Alkaloids 
EXPERIMENT OBSERVATION INFERENCE 
1.Dragendroff’s test: 
The extract was treated 
withDragendroff’s reagent 
(potassium bismuth iodide 
solution) 
 
 
Orange brown Precipitate 
was formed 
 
 
Presence of alkaloids 
2.Mayers’ reagent’s: 
The extract was treated 
with Mayer’s (potassium 
mercuric iodide solution) 
reagent 
 
Precipitate formed 
 
Presence of alkaloids 
3.Wagner’s reagent: 
The extract was treated 
with wagner’s reagent 
(iodide and potassium 
triiodide solution) 
 
Reddish brown Precipitate 
was formed 
 
Presence of alkaloids 
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Test for Glycosides 
1.Brontragers test: 
To the extract add dilute 
H2SO4 and filtered. Filtrate 
was extract with little 
chloroform layer was 
separated out and add equal 
volume of dilute NH3. 
 
 
Red colourobserved in 
ammonical layer 
 
 
 
Presence of glycosides 
 
Test for Saponin glycosides 
1.Foam test: 
Shake the extract with 
water 
 
Foam was produced/formed 
 
Presence of saponin 
Glycosides 
 
Test for Tannins and Phenolic compounds 
1.Ferric chloride test: 
To the aqueous extract few 
drops of ferric chloride 
solution were added 
 
Dark black colour formed 
 
Presence of tannins and 
phenolic compounds 
2.Bromine water test: 
To the aqueous extract is 
treated with bromine water 
 
Discoloration of bromine 
Water 
 
Presence of tannins and 
phenolic compounds 
3.KMnO4test: 
To the aqueous extract is 
treated with dilute KMnO4 
 
Discoloration of solution 
 
Presence of tannins and 
phenolic compounds 
 
Test for Reducing sugar 
1.Benedict’s test: 
 0.5ml of extract solution 
1ml of water 5 to 8 drops of 
fehlings solution was added 
 
No brick red precipitate 
 
Absence of reducing sugar 
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Test for Amino acids 
1.Ninhydrin test: 
The aqueous extract is 
heated 
with 5%ninhydrin solution 
on 
boiling water bath for 10 
min. 
 
 
No purple coloured 
 
 
Presence of amino acids 
2.The aqueous extract is 
treated with solution  
sodium hydroxide  and lead 
acetate solution and boiled 
 
No black precipitate is 
formed 
 
Presence of amino acids 
 
Test for Flavonoids 
1. Shinoda test: 
To the methanol extract add 
potassium hydroxide 
solution and then 10% 
ammonia. 
 
Yellow colour Precipitate 
formed. 
 
Presence of flavonoids 
2.To the ethanol extract, add 
few drops of Lead acetate 
solution. 
 
Yellow colour Precipitate 
formed. 
 
Presence of flavonoids. 
 
Test for Terpenoids 
1.4gm of extract was 
treated with 0.5ml of acetic 
anyhydride and 0.5ml of 
chloroform and added 
concentrated solution of 
sulphuric acid 
 
 
No Red violet colour was 
obtained 
 
 
Absence of terpenoids 
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Test for Steroids 
1.Libermann- Buchard Test: 
To extract add chloroform 
solution a few drops of 
acetic anhydride and 1ml of 
con. H2SO4 were added 
through the side of the test 
tube and set aside for a 
while. 
 
 
Brown ring was formed at 
the junction. 
 
 
Presence of steroids 
2. Salkowski Test: 
To the extract add 
chloroform solution few 
drops of con. H2SO4 was 
added shaken and allowed 
to stand. 
 
 
Greenish fluorescence was 
formed. 
 
 
Presence of steroids 
3. Libermann’s Reaction: 
Mix 3ml of extract with 
3ml of acetic anhydride, 
heat and cool. Add few 
drops of Con. H2SO4. 
 
 
Blue colour was formed 
 
 
Presence of steroids 
 
6. 8.Preparation of Transdermal Patch44 
Three batches of drug loaded (ME of Acalypha indica Linn.) transdermal 
patches were prepared using drug with different polymer ratio (1:1, 1:2, and 1:4). 
Weighed quantity of polymer  was dissolved in calculated quantity of water and heated 
on a water bath. Calculated amount of extract was added to the above mixture and 
stirred well until a homogenous mixture was formed. Then calculated amount of 
permeation enhancer and Glycerin were added. 
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The resultant mixture was poured into a petridish and air dried at room 
temperature for 24hrs.The patches are then peeled off from the petridish with the help 
of a knife and kept in desiccator. 
Calculation 
  Diameter of glass plate  = X cm    
  Radius of glass plate   = Y cm    
   Area of glass plate =  ߨr2 (π=3.14)   
      = 3.14 × (y)    
      = Z cm2    
  Z/X= Area/diameter  = capacity (ml) 
6.9.Calibration  Curve of Methanolic Extract of Acalypha indica Linn. 
6.10. Preparation of phosphate buffer pH 7.4 
Phosphate buffer pH 7.4 was prepared as per the method described in I.P 1996 
using disodium hydrogen phosphate and sodium hydroxide. The pH was adjusted to 7.4 
prior to quantitative estimation. 
6.11. Preparation of calibration curve of Acalypha indica Linn. extract in 
phosphate buffer  
pH 7.4 
Accurately weighed quantity (100mg) of MEA was transferred into a 100ml 
volumetric flask and dissolved in small amount of phosphate buffer (pH 7.4) and made 
upto the volume with same buffer to make the standard stock solution of 1 mg/ml. 
From the stock, 1ml was taken in 10ml volumetric flask and made up the 
volume with the buffer; from this solution 0.5ml to 3ml solution was transferred to 
10ml volumetric flask and made upto required volume with more buffer and the 
resulting concentration ranges from 5 to 50 µg/ml. The absorbance of these solutions 
was determined at 260nm using UV spectrophotometer.The calibration curve was 
constructed between the absorbance and concentration.    
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6.12. Physico chemical evaluation of Acalypha indica Linn. 
Transdermal patch:45,46,47,66,67 
 Formulated patches were subjected to the preliminary evaluation tests. Patches 
with any imperfections, entrapped air, or differing in thickness, weight (or) content 
uniformity were excluded from further studies.  
 
1. Uniformity of weight  
This was done by weighing five different patches of individual batch taking the 
uniform size at random and calculating the average weight of three. The tests were 
performed on patch which was dried at 60˚C for 4 hrs prior to testing. The result is 
shown in Table No:18 
 
2. Thickness of the Patch 
 The thickness of the patch was assessed by using digital vernier caliper at 
different points of the patch. From each formulation three randomly selected patches 
were used. The average value for thickness of a single patch was determined.61 The 
results are shown in TableNo: 19 
3.Drug content determination  
The patch were taken and added to a beaker containing 100 ml of Phosphate 
buffer saline pH 7.4. The medium was stirred magnetic bead for 5 hrs.The solution was 
later filtered and analyzed for drug content with proper dilution at 260 nm 
spectrophotometrically. The results are shown in Table No: 20 
 
4. Folding Endurance  
This was determined by repeatedly folding one patch at the same place till it 
broke. The number of times the patch could be folded at the same place without 
breaking gave the value of folding endurance. The result shown in Table No :21 
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5. Percentage Moisture uptake:  
The patch were weighed accurately and placed in desiccators containing 
aluminiumchloride. After 24 hrs, the film were taken out and weighed. The percentage 
moisture uptake was calculated as the difference between final and initial weight. With 
respect to initial weight. It is calculated by using following formula.54 
 
        Final weight –Initial weight  
Percentage moisture content =  X 100 
   Initial weight  
 
The results are shown in Table No: 22 
 
6. Percentage Moisture content 68 
The patch were weighed and kept in desiccators containing calcium chloride. 
After 24hrs the patch were taken out and weighed. The percentage moisture content was 
calculated using the following formula.  
 
Initial weight –Final weight  
  Percentage moisture content =                                                X 100 
Initial weight 
The result shown in Table No: 23 
 
7.Determination of surface pH 69 
The patches were allowed to swell by keeping them in contact with 1 ml of 
distilled water for 2 h at room temperature and pH was noted down by bringing the 
electrode in contact with the surface of the patch, allowing it to equilibrate for 1 min. 
The result are shown in Table No:24 
 
8. Percent Elongation 70 
When stress is applied, a patch sample stretches and this is referred to as strain. 
Strain is basically the deformation of patch divided by original dimension of the sample. 
Generally elongation of patch increases as the plasticizer content increases. It is 
calculated by using following formula.  
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           Increase in length of patch   
  Percentage elongation =                                                   X 100 
Initial length of patch 
 
The result shown in Table No: 25 
 
9. Tensile strength  
Tensile strength is the maximum stress applied to a point at which the patch 
specimen breaks . It is calculated by the applied load at rupture divided by the cross-
sectional area of the strip as given in the equation below:   
      Load at failure 
Percentage elongation =                                                     X 100  
      Patch thickness x Patch  width 
 
The result shown in Table No: 26 
 
Cellophane Membrane Treatment:48 
Cellophane membrane was boiled in the distilled water for 1 hr and washed with 
fresh distilled water for three times and kept in ethanol for 24 hrs. It was washed with 
distilled water and treated with 0.3% sodium sulphite and soaked in distilled water for 2 
min at 60°C followed by acidified with 0.2% sulphuric acid. Finally the membrane was 
dipped in boric buffer (pH 9) till it is used for permeation study. 
 
Drug Permeation Studies:49 
The in-vitro release rate of Acalypha indica Linn. transdermal patch were 
evaluated by open ended tube through using PB pH 7.4 as diffusion medium up to 12 
hours studies. The cellophane membrane is tided in one end of the tube and then 
immersed in the receptor compartment containing 400ml of PB pH7.4.Which was 
stirred at medium speed and maintained at 37°C±2°C. Samples were withdrawn at 
regular time intervals and the same volume was replaced by fresh diffusion medium. 
(79) The samples were analyzed using UV – visible spectrophotometer (Shimadzu 
UV1700) set at 260 nm. The result is shown in Table No:30 and Fig.No:29 
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6.13.Experimental conditions of ex- vivo transdermal permeation study 
         of H4 formulation 54,55,56,57,58,59,60 
 Ex-vivo Transdermal permeation studies carried out using Goat abdomen skin  
 The receptor compartment consisted of 400ml of Phosphate buffer (pH 7.4) in 
500 ml beaker  
 Temperature was maintained at 37 ± 0.5°C and stirred at 900 rpm  
 The Acalypha indica Linn.Transdermal patch was placed in Goat abdomen 
skin and tied to the one end of open-ended glass cylinder that was then dipped 
into freshly prepared phosphate buffer on magnetic stirrer  
 Samples were taken from receptor medium at 0, 5, 10, 15, 30, 45, 60, 120, 
180, 240 and 300, 360, 420,480 , 540, 600, 660, 720 min  
 Periodically 5ml of sample was withdrawn and same volume of medium was 
replaced with fresh buffer  
 All the Samples were assayed spectrophotometrically at 260 nm using PB 7.4 
pH as blank  
 
The result shown in Table No: 31 and Fig No:33 
6.14. Release Kinetics 60,61,62,63,64,65 
Data obtained from in-vitro release studies were fitted to various kinetic 
equations. The kinetic models used are zero order equations (Q=k0t), First order 
equation {ln (100 – Q) =ln Q – klt}, Higuchi equation (Q=kt1/2), Hixson and crowell 
model Qt1/3 Vs t and Qt2/3 Vs – Modified root cube equation. Further, to find out the 
mechanism of drug release, first 60% drug release was fitted in Korsmeyer and Peppas 
equation (Q=kptn). Where, Q is the percent of the drug release at time t and k0 and kt 
are the coefficients of the equations and ‘n’ are the release exponent. The ‘n’ value is 
used to characterize different release mechanism. 
The order of drug release can be assessed by graphical treatment of drug release 
data.  
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A plot of cumulative % drug release versus time would be linear if the drug 
release follows zero order (i.e. Concentration independent release).  
 
A plot of log of % remaining drug versus time would be linear, if the drug 
release follows first order (i.e. Concentration dependent release)  
 
The linear equation for zero order drug release plot is:  
Ct = C0 – Kt 
Where,  
Ct = concentration remaining at time t,  
Co = original concentration,  
t = time,  
K = release rate  
The linear equation for first order release plot is  
 
logC0Kt  
Log C =            ------------  
2.303  
A matrix device as the name implies, consists of drug dispersed homogeneously 
throughout a polymer matrix 
 
In this model, drug in the outside layer exposed to the bathing solution is 
dissolved first and then diffuses out of the matrix. This process continues with the 
interface between the bathing solution and the solid drug moving towards the interior. 
Obviously, for this system to be diffusion controlled, the rate of dissolution of drug 
particles within the matrix must be much faster than the diffusion rate of dissolved drug 
leaving the matrix. 
Hydrophilic matrix tablets contain a water swellable polymer. On 
[1 – Mt / M] 1/3 = 1-kt  
Where,  
Mt = mass of drug release at time t,  
M = mass release at the infinite time,  
K = rate of erosion,  
t = time  
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Thus a plot of [1 – Mt / M] 1/3 versus the time will be linear. If the release of 
drug from the matrix is erosion controlled.  
 
In order to ascertain whether the drug release occurs by diffusion or erosion, the 
drug release data was subjected to following modes of data treatments.  
1) Amount of drug release versus square root of time (Higuchi Plot).  
2) [1 – Mt / M] 1/3 versus time.  
 
6.15. Stability studies:  
a) Stability:50,51,71 
Stability is official defined as the time lapse during which the drug product 
retains the same property and characteristics that it possessed at the time of 
manufacture. This process being early development phases. 
 
Instability in modern formulation is often undetectable only after considerable 
storage period under normal conditions. To assess the stability of a formulated product 
it is usual to expose it to high stress conditions to enhance deterioration and therefore 
the time required for testing is reduced. Common high stresses are temperature and 
humidity. This will eliminate unsatisfactory formulation.  
 
b) Strategy of stability testing:  
¾ The study of drug decomposition kinetics  
¾ The development of stable dosage form  
¾ Establishment of expiry date for commercially available drug product is some 
of the needs of stability testing  
¾ Data from which study should be provided on at least 3 primary batches of the 
drug product  
¾ The batches should be manufactured to a minimum of pilot scale  
¾ Important point of view of the safety of the patient, patient relieves a uniform 
dose of drug throughout the shelf life of the product  
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Table No.5: Stability condition chart 
Intended 
Storage 
Condition 
StabilityTest 
Method 
ICH Test 
Temperature and 
Humidity (period in 
months) 
WHO Test 
Temperature and 
Humidity(period in 
Months) 
Room 
Temperature 
Long term 25±20C/60±5%RH 25±20C/60±5%RH or 
30±20C/65±5%RH 
30±20C/75±5%RH 
Intermediate 30±20C/65±5%RH 30±20C/65±5%RH 
Accelerated 40±20C/75±5%RH 40±20C/75±5%RH 
Refrigerated Long term 
Accelerated 
50C/ambient 
25±20C/60±5%RH 
5±30C 
25±20C/60±5%RH  or 
30±20C/65±5%RH 
Freezer Long term -200C/ambient -200C±50C 
 
6.16. Screening of Antimicrobial activity of Acalypha indica Linn. 
6.16.1. Anti-Bacterial Activity52,53 
Principle 
  Discs impregnated with known concentration of antibiotics discs are placed on 
agar plate that has been inoculated (or) seeded uniformly over the entire plate with a 
culture of the bacterium to be tested. The plate is incubated for 18-24 hrs at 37oC. 
During this period, the antibacterial agent diffuses through the agar and may prevent the 
growth of organism. Effectiveness of susceptibility is proportional to the diameter of 
inhibition of zone around the disc. Organisms which grow up to the edge of the disc are 
resistant. 
A) Materials Required  Peptone, Sodium Chloride, Dil. Sodium 
Hydroxide, Dil. Sulphuric acid, Agar, Distilled water, pH paper, Conical flask, 
Culture tubes, Glass rod, Non-absorbant cotton, Autoclave- Micropipette, Petri 
dishes and Incubator. 
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 B) Experimental Parts 
Organisms used : Bacillus subtilis, Staphylococcus aureus, Escherichia coli, 
     Klebseilla pneumonia, 
Media used  : Nutrient Agar. 
Test used  : Methanolic extract of Acalypha indica Linn., patch, 
Standard  : Ciprofloxacin, Nystatin 
C) Preparation of Nutrient Agar 
  8.2 gm of agar powder was dissolved in 250 ml of water. The medium was 
steamed in boiler to precipitate any heat coagulable material. Then the medium was 
filtered. The filtrate was distributed in 5ml quantity in to culture tubes. The tubes were 
plugged with non-absorbent cotton. The medium in the tubes were sterilized by 
autoclave not less than 15 minutes at 15 pounds per sq. inch at 121oC. 
D) Preparation of Nutrient Broth 
  15.2 gm of nutrient broth agar was dissolved in 400 ml of water. To this 
required quantity of agar was added and heated in a beaker in order to dissolved agar. 
Then it was distributed in to culture tubes and plugged with cotton and sterilized in 
autoclave. 
E) Inoculation of Culture Media 
  From nutrient broth solution, a quantity of 10 ml was taken in three test tubes 
inoculation needle or loop was heated in to red condition in the hot zone of Bunsen 
burner. The needle is allowed to cool or its own by holding it in the zone of sterility of 
Bunsen flame. The tube containing specimen culture grasped in the left hand probably 
in the horizontal or inclined position but not vertical. Mouth of the culture tube was 
passed through the Bunsen flame to kill any organisms that may fall in to the culture. 
Inoculation needle was inserted in to the specimen, culture tube containing actively  
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growing bacteria. The growth on the surface of agar was gently touched with the tip of 
the needle. The inoculation of charged needle was dripped in to the test tubes containing 
nutrient broth. The test tubes were kept aside for 24 hrs at 37oc for 24 hours. 
F) Preparation of Paper Disc 
  By using standard punching machine what man filter paper was cut and standard 
paper of 6.0 mm diameter was prepared. The paper discs were sterilized in a hot air 
oven at 160oC for 1hour. The paper discs were then impregnated with the test solution. 
6.16.2. Anti-Fungal Activity53,54, 
Principle 
  Discs impregnated with known concentration of antibiotics discs are placed on 
Modified Sabouraud’s Glucose agar plate that has been inoculated (or) seeded 
uniformly over the entire plate with a culture of the fungi to be tested. The plate is 
incubated for 3days 18-24 hrs at 37oC. During this period, the antifungal agent diffuses 
through the agar and may prevent the growth of organism. Effectiveness of 
susceptibility is proportional to the diameter of inhibition of zone around the disc. 
Organisms which grow up to the edge of the disc are resistant. 
A) Materials Required 
  Glucose, Peptone, yeast extract, Glycerin mono stearate, Olive oil, Tween 80, 
Chloramphenicol,  Agar, Distilled water, pH paper, Conical flask, Culture tubes, Glass 
rod, Non-absorbant cotton, Autoclave, Micropipette Petri dishes and Incubator.75 
B) Experimental Parts 
Organisms used : Candida albicans,  Aspergillus niger. 
Media used  : Modified Sabouraud’s Glucose Agar medium 
Test used  : Methanolic extract of Acalypha indica Linn. patch, 
Standard   : Ciprofloxacin, Nystatin 
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7. RESULTS AND DISCUSSIONS 
7.1. Absorption maxima (λ max) of Methanolic Extract of 
         Acalypha   indica Linn. 
 
 
          Fig No.17: Absorption maxima (λ max) of Methanolic Extract of 
               Acalypha   indica  Linn.  
 
From the sharp peak observed at 260 nm, further measurements were taken at 260 nm. 
 
UV-Vis Spectrum
ACIC
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7.2. Standard curve of Methanolic  Extract of Acalypha indica Linn. : 
Table No:. 6: Standard Cure of Extract of Acalypha indica Linn.   
 
 
Concentration 
(g/ml) 
Absorbance 
 
AverageSD 
0 0.000 0.000 
5 0.091 0.001 
10 0.182 0.001 
15 0.273 0.001 
20 0.363 0.001 
25 0.459 0.008 
  
 
 
                                                                                                     
              
 
Fig No.18: Standard Cure of Methanolic Extract of Acalypha indica Linn. 
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7.3. Physical appearance 
Colour  :  Green 
Taste  :  Bitter taste 
Solubility        :         Freely soluble in Methanol 
7.4. Extraction of Leaves of Acalypha indica Linn. 
MEA was carried out as per the procedure described in 6.3 and the yield of the 
extract was 6.5%w/v. 
7.5. Phytochemical Studies 
The phytochemical studies revealed that the presence of alkaloids, saponins, 
tannins, phenolic compounds, flavonoids and sterol. 
Table No.7: Phytochemical constituents 
 
 
  
 
 
 
(+) Presence of constituents 
(-) Absence of constituents 
S.NO Chemical 
constituents 
Alcoholic 
extract 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Alkaloids 
Saponins 
Tannins 
Phenolic compounds 
Flavonoids 
Steroids 
Glycosides 
Amino acids 
Reducing sugar 
   Terpenoids 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
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7.6. Hygroscopic Nature 
Table No: 8 Hygroscopic Nature determination 
At Room 
Temperature 
75%RH at 40
0
C 
Sample No-1  Sample No-1 
Weight gain 
observed-Nil 
Weight gain 
observed-Nil 
 
From the results, it is observed that the prepared Transdermal patch is non 
hygroscopic in nature 
7.7. Compatibility study 
FTIR studies 
 
   
Fig No. 19: FTIR Spectrum of Methanolic Extract of  Acalypha indica Linn. 
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Table No. 9: FTIR Interpretation of Methanolic Extract of Acalypha indica Linn. 
  
Wave number (cm
-1
) Functional Group 
3782.15 OH Stretching 
3346.50 OH Stretching 
3055.53 C-H Stretching 
2923.11 C-H Stretching 
1639.23 C-H Stretching 
 
 
  
Fig No. 20: FTIR spectrum of Pectin 
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Table No.10: FTIR Interpretation of Pectin 
 
 
  
 
 
 
 
 
                               Fig No. 21:  FTIR of  Spectrum Sodium alginate 
 
 
 
Wave number (cm-1) Functional groups 
3442.09 C=O stretching 
1931.41 C-C stretching 
1742.41 C-C stretching 
1232.88 OH bending 
914.15 C-O Stretching 
769.94 CH Rocking 
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Table No.11: FTIR Interpretation of Sodium alginate 
Wave number (cm
-1
) Functional group 
3428.53 O-H Stretching 
2925.88 C-H Stretching 
1620.09 C=O Strtching 
1416.26 C-O Stretching 
1033.17 C-C Stretching 
949.59-670.01 C-H (Out plane bending) 
 
 
 
 
Fig No. 22: FTIR Spectrum of HPMC 
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Table No. 12: FTIR Interpretation of HPMC 
  
  
  
 
 
 
  
  
 
 
Fig No. 23: FTIR Spectrum of Pectin Formulation(P2) 
 
 
 
 
S.No. Wavenumber (cm
-1
) Functional groups 
1 3445.74 O-H stretching 
2 2922.70 C-H stretching 
3 1645.52,1459.59 C-C multiple bond 
stretching 
4 1377.05 O-H stretching 
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Table No.13 :FTIRInterpretation of Pectin formulation 
Wave number (Cm
-1
) Functional groups 
1644.88 C=C stretching 
1412.89 O-H bending 
1045.91 C-O stretching 
1115.29 C-O stretching 
1045.91 C-O stretching 
    
 
Fig No. 24:  FTIR Spectrum of HPMC formulation(H4) 
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Table No.14: FTIR Interpretaion of HPMC formulation 
 
 
 
 
 
 
 
Fig No.25: FTIR Spectrum of Sodium Alginate Formulation(s7) 
 
 
 
 
 
Wave number (Cm
-1
) Functional groups 
3339.75 O-H stretching 
1412.89 O-H bending 
1045.91 C-O stretching 
1115.29 C-O stretching 
1045.91 C-O stretching 
954.38 C-H ( Outplane bending) 
675.03 C-H ( Outplane bending) 
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Table No.15: FTIR Interpretation of Sodium alginate formulation 
Wave number (Cm
-1
) Functional groups 
3776.66 O-H stretching 
3324.72 O-H stretching 
1643.60 C=C stretching 
1265.8 C-H ( in plane bending) 
679.94 C-H ( Out plane bending) 
 
 The FTIR graphs of drug ,excipients and formulations results showed that there 
is no extra peak (or) broadening of peaks were observed and thus it indicates that there 
is no incompatibility between drug and excipients.
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7.8. Physico chemical evaluation of  Methanolic  Extract of Acalypha indica Linn. Transdermal patch 
 
Table No. 16:Physico chemical evaluation of Methaolic Extract of Acalypha indica Linn.Transdermal patch 
Formulation 
code 
Uniformity 
of weight 
(g) 
Thickness 
   (mm) 
 Drug 
content 
     (%) 
Folding 
Endurance 
e(no’s) 
Moisture
Uptake 
   (%) 
 Moisture 
Content 
     (%) 
Surface 
pH  
Percent 
Elongation
(% mm) 
Tensile 
Strength 
(Kg/mm
2
) 
Pectin 
(P) 
P1 0.23±0.73 0.17±0.52 95.47±0.05 260±0.06 2.06±0.54 0.572±0.60 6.4±0.05 66±0.52 3.410±0.05 
P2 0.37±0.1 0.23±0.47 95.82±0.65 270±0.57 2.14±0.08 1.925±0.4 7.2±0.10 85±043 5.400±0.65 
P3 0.41±0.45 0.29±0.61 95.70±0.68 240±0.82 1.97±1.03 1.624±0.05 6.2±0.72 78±1.21 6.461±0.83 
HPMC(
H) 
H4 0.37±0.01 0.35±0.15 96.24±0.65 285±0.57 3.57±0.07 3.271±0.4 7.4±0.11 130±0.21 7.660±0.21 
H5 0.26±0.20 0.32±0.83 96.07±0.29 259±0.41 2.76±0.67 2.967±0.03 7.2±0.43 125±0.72 6.461±0.46 
H6 0.17±0.25 0.24±0.59 95.93±0.81 245±0.64 2.95±0.34 3.431±0.62 7.2±0.9 118±0.92 5.410±0.72 
Sodium 
alginate 
(S) 
S7 0.28±0.61 0.11±0.51 96.00±1.04 237±0.38 0.96±0.41 1.481±0.45 7±0.65 98±0.06 3.800±0.20 
S8 0.25±0.2 0.18±0.32 96.01±0.47 267±1.0 1.88±0.19 0.192±0.08 6.6±0.30 113±0.89 4.660±0.89 
S9 0.31±1.26 0.20±0.45 95.76±0.70 245±0.92 1.89±0.02 1.923±1.01 6.6±0.27 86±0.79 6.410±1.63 
Mean±S.D: n=3  
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         The nine (P1,P2,P3,H4,H5,H6,S7,S8,S9) batches of drug loaded films with different ratios 
of different polymers were subjected to various physicochemical evaluations. 
           Based on thickness, uniformity of weight, folding endurance, percentage moisture uptake 
and tensile strength,the formulations P2, H4, and S7 were selected for further studies. 
7.9. Optimized formula of Acalypha indica Linn. Transdermal patch 
Table No.17:Optimized formula of Acalypha indica Linn. Transdermal patch 
 
7.10. Selected Formulations 
 
 
Fig No. 26: Transdermal Patch of (P2) Pectin formulation 
S.NO Ingredients P 
(Pectin) 
H 
(HPMC) 
S 
(Sodium alginate) 
1 Extract (mg) Acalypha indica 
Linn.. 
10 10 10 
2 Polymer (mg) 10 20 40 
4 DMSO/SLS(ml) 0.3 0.3 0.3 
5 Glycerin (ml) 0.3 0.3 0.3 
3 Water (ml) q.s q.s q.s 
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     Fig No .27: Transdermal Patch of (H4)HPMC Formulation 
 
 
 
Fig No. 28: Transdermal Patch of (S7) Sodium alginate formulation 
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7.11. Physicochemical Evaluation of Selected formulations (P2,H4 and S7) 
 
Table No. 18: Uniformity of  weight 
 
 
 
 
 
 
 
   
  Mean ± S.D: n= 3 
 
Table No. 19: Thickness of the patch 
S.No Formulation code Thickness (mm) 
 
1 Pectin 0.23±0.47 
2 HPMC 0.35±0.15 
 
3 Sodium alginate 0.18±0.32 
   
  Mean± S.D:n=3 
Table No. 20: Determination of Drug content 
S.No 
 
Formulation code % Drug content 
1 
 
Pectin 95.82±1.21 
2 
 
HPMC 96.24±0.65 
3 
 
Sodium alginate 96.01±1.05 
   
  Mean ± S.D: n=3  
S.No 
 
Formulation code Weight(g) 
1 
 
Pectin 0.19±0.1 
2 
 
HPMC 0.21±0.01 
3 
 
Sodium alginate 0.15±0.2 
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Table No. 21: Folding Endurance 
S.No 
 
Formulation code Folding Endurance 
(No’s) 
1 
 
Pectin 255±1.5 
2 
 
HPMC 265±0.57 
3 
 
Sodium alginate 260±1.0 
   
        Mean ± S.D: n =3 
Table No. 22: Percentage Moisture Uptake 
S.No 
 
Formulation code 
 
% Moisture uptake 
1 
 
Pectin 2.14±0.08 
2 
 
HPMC 1.57±0.07 
3 
 
Sodium alginate 2.88±0.19 
   
                       Mean ± S.D: n=3 
Table No. 23: Percentage Moisture Content 
S.No 
 
Formulation code % Moisture content 
1 
 
Pectin 1.92±0.6 
2 
 
HPMC 1.67±0.4 
3 
 
Sodium alginate 1.95±0.2 
  
     Mean ± S.D: n=3 
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                                           Table No. 24: Surface pH  
S.No 
 
Formulation code Surface pH of patches 
1 
 
Pectin 7.2±0.10 
2 
 
HPMC 7.4±0.11 
3 
 
Sodium alginate 6.6±0.30 
  
            Mean ± S.D: n=3 
 
Table No. 25: Percent Elongation 
S.No 
 
Formulation code % Elongation (%mm) 
1 
 
Pectin 92±0.43 
2 
 
HPMC 97±0.26 
3 
 
Sodium alginate 89±1.04 
  
      Mean ± S.D: n=3 
Table No.26: Tensile Strength 
S.No 
 
Formulation code Tensile strength (kg/mm
2
) 
1 
 
Pectin 5.300±0.65 
2 
 
HPMC 6.660±0.25 
3 
 
Sodium alginate 4.245±0.78 
 
Mean ± S.D: n=3 
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Table No. 27: In-vitro drug release profile of  P2 
 
S.No Time (min) 
 
% Drug release 
1 0 0 
2                                5 0.51± 0.23 
3                                10 0.80 ± 0.45 
4                               15 1.54 ± 0.44 
5                                30 2.20 ± 0.76 
6                               45 5.45 ± 1.78 
7                               60 10.00 ± 0.59 
8                                120 19.38± 1.23 
9                               180 25.48 ± 0.61 
10                             240 34.56 ±1.24 
11                              300 38.73 ± 1.90 
12                              360 44.54±1.54 
13                              420 49.00± 0.23 
14                             480 57.64± 1.34 
15                            540 62.28 ± 0.91 
16                             600 68.24± 0.72 
17                             660 77.36± 0.61 
18                            720 85.24 ± 0.72 
 
                          Mean±S.D:n=3 
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Fig No. 29: In- vitro drug release profile of P2 
 
Table No. 28 : In- vitro drug release profile of H4 
S.No 
 
Time (min) % Drug release 
1 
 
0 0 
2 
 
5 0.33 ± 0.07 
3 
 
10 0.74± 0.64 
4 
 
15 1.00 ± 0.27 
5 
 
30 2.14 ± 0.05 
6 
 
45 4.23 ± 0.73 
7 
 
60 8.00 ± 0.73 
8 
 
120 17.31 ± 1.2 
9 
 
180 23.45 ± 0.05 
10 
 
240 31.23 ± 0.59 
11 
 
300 38.42 ± 0.01 
12 
 
360 45.58 ± 0.48 
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13 
 
420 51.25 ± 0.12 
14 
 
480 57.25 ± 0.73 
15 
 
540 68.46 ± 0.89 
16 
 
600 73.46 ± 0.41 
17 
 
660 75.34±0.23 
18 
 
720 70.56±0.41 
   
      Mean S.D:n=3 
 
 
 
                          Fig No. 30: In- vitro drug release profile of  H4 
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Table No.  29 : In- vitro drug release profile of S7 
S.No 
 
Time (min) % Drug release 
1 
 
0 0 
2 
 
5 0.61 ± 0.64 
3 
 
10 1.45 ± 0.52 
4 
 
15 2.01 ± 0.03 
5 
 
30 4.27 ± 0.09 
6 
 
45 6.98 ± 0.62 
7 
 
60 11.53 ± 0.17 
8 
 
120 20.42 ± 0.06 
9 
 
180 26.56 ± 0.06 
10 
 
240 34.28 ± 0.41 
11 
 
300 41.58 ± 0.24 
12 
 
360 45.95 ± 0.41 
13 
 
420 52.00 ± 0.06 
14 
 
480 58.74 ± 0.92 
15 
 
540 65.48 ± 0.68 
16 
 
600 71.41 ± 0.46 
17 
 
660 76.76 ± 0.86 
18 
 
720 84.41 ± 0.53 
   
                           Mean± S.D n=3 
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Fig No. 31:  In -vitro drug release profile of S7 
 
Table No.30 : Comparative in- vitro drug release profile 
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S.No Pectin HPMC Sodium alginate 
1 
 
0 0 0 
2 
 
0.51± 0.23 0.33 ± 0.07 0.61 ± 0.64 
3 
 
0.80 ± 0.45 0.74± 0.64 1.45 ± 0.52 
4 
 
1.54 ± 0.44 1.00 ± 0.27 2.01 ± 0.03 
5 
 
2.20 ± 0.76 2.14 ± 0.05 4.27 ± 0.09 
6 
 
5.45 ± 1.78 4.23 ± 0.73 6.98 ± 0.62 
7 
 
10.00 ± 0.59 8.00 ± 0.73 11.53 ± 0.17 
8 
 
19.38± 1.23 17.31 ± 1.2 20.42 ± 0.06 
9 
 
25.48 ± 0.61 23.45 ± 0.05 26.56 ± 0.06 
10 
 
34.56 ±1.24 31.23 ± 0.59 34.28 ± 0.41 
11 38.73 ± 1.90 38.42 ± 0.01 41.58 ± 0.24 
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Mean ±S.D n=3 
 
 
                  Fig No.3 2: Comparative in -vitro drug release profile 
 
 
 
12 
 
44.54±1.54 45.58 ± 0.48 45.95 ± 0.41 
13 
 
49.00± 0.23 51.25 ± 0.12 52.00 ± 0.06 
14 
 
57.64± 1.34 65.26 ± 0.73 58.74 ± 0.92 
15 
 
62.28 ± 0.91 68.46 ± 0.89 65.48 ± 0.68 
16 
 
68.24± 0.72 73.46 ± 0.41 71.41 ± 0.46 
17 
 
77.36± 0.61 75.34±0.23 76.76 ± 0.86 
18 
 
80.24 ± 0.72 70.56±0.41 83.41 ± 0.53 
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  The selected 3 batches of formulations Pectin (P2), Sodium alginate (S7) and HPMC 
(H4) were subjected ex-vivo diffusion studies. Formulation H4 showed sustained release in a 
controlled manner upto 12 hrs. So this has been selected for ex-vivo and stability studies. 
 
 
Fig No. 33 : Ex- vivo diffusion study (H4) 
 
 
 
Fig No. 34 :Goat abdomen skin tied on open ended cylinder 
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                             Table No: 31. Ex- vivo Transdermal Permeation of  H4 
S.No Time in min % Drug release 
1 
 
0 0 
2 
 
5 0.30±0.15 
3 
 
10 0.43±0.53 
4 
 
15 0.70±0.71 
5 
 
30 1.35±0.62 
6 
 
45 2.23±0.45 
7 
 
60 3.12±0.47 
8 
 
120 5.45±0.16 
9 
 
180 11.28±0.32 
10 
 
240 20.45±0.06 
11 
 
300 27.70±0.83 
12 
 
360 35.20±0.71 
13 
 
420 40.56±0.71 
14 
 
480 50.24±0.63 
15 
 
540 53.26±0.68 
16 
 
600 62.43±0.24 
17 
 
660 68.73±0.63 
18 
 
720 70.24±0.58 
19 
 
780 65.24±0.25 
  
  Mean ± S.D: n= 3 
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Fig No. 35: Ex- vivo Transdermal Permeation of H4 
 
7.12. Release Kinetics 
            Table No.32 : In-vitro values are subjected to various kinetics equations  
 
 
Formulation 
Code 
 
P2 
Correlation Coefficient (r
2
) 
 
 
Zero order First order Higuchi Korsmeyrpeppas ‘n’-Release 
Exponent 
0.991 0.763 0.972 0.927 0.86 
H4 
 
0.991 0.797 0.963 0.984 0.83 
S7 
 
0.992 0.756 0.973 0.995 0.87 
Ex- vivo(H4) 
 
0.990 0.867 0.930 0.995 0.86 
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Fig No. 36: Release kinetics of P2 
 
 
 
Fig No. 37 
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Fig No. 38 
 
 
 
 
Fig No. 39 
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Release kinetics of H4 
 
Fig No. 40 
 
 
 
 
Fig No. 41 
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Fig No.42 
 
 
 
Fig No. 43 
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Release kinetics of S7 
 
 
Fig No. 44 
 
 
 
FigNo.45 
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Fig No.46 
 
 
 
Fig No. 47 
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Fig No. 48: Ex-vivo Release of H4 
 
 
Fig No. 49 
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Fig No. 50 
 
 
 Fig No.51 
 
The release kinetics showed that the H4 formulation followed Zero order and non-fickian 
diffusion. 
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7.13. Stability study of Methanolic Extract of Acalypha indica Linn.Transdermal Patch 
Table No: 33 
 
Parameter Room 
temperature 
40±2
0
C& RH 
70±5% 
Visual Appearance Transparent Transparent 
Initial No change No change 
At the end of 1
st
 month No change No change 
At the end of 2
nd
 month No change No change 
At the end of 3
rd
 month No change No change 
Colour Dull white Dull white 
Initial No change No change 
At the end of 1
st
 month No change No change 
At the end of 2
nd
 month No change No change 
At the end of 3
rd
 month No change No change 
Texture Smooth Smooth 
Initial No change No change 
At the end of 1
st
 month No change No change 
At the end of 2
nd
 month No change No change 
At the end of 3
rd
 month No change No change 
Drug content No change No change 
Initial 96.24% 96.24% 
At the end of 1
st
 month 96.22% 96.14% 
At the end of 2
nd
 month 95.95% 95.81% 
At the end of 3
rd
 month 95.21% 95.06% 
 
 The stability studies of H4 formulation of Methanolic Extract of Acalypha indica 
Linn.Transdermal Patch was carried out for 3 months as per the procedure described in the 
Chapter.6. During this period, the formulations were stable and showed no significant changes in 
Visual appearance, Colour, Texture and Drug content. 
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7.14. Screening of Antimicrobial activity of  Acalypha indica Linn. 
                                                   FUNGI 
    
 Fig No. 52. Aspergillusniger    Fig No. 53. Candida albicans 
 
 
      GRAM POSITIVE BACTERIA 
   
 Fig No. 54.Bacillus subtilis   Fig No.55.Staphylococcus aureus 
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GRAM NEGATIVE BACTERIA 
   
 Fig No. 56.E.coli      FigNo. 57.Pseudomonas aeruginosa 
 
     
     Fig No. 58. Klebsiella pneumonia 
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                                            Table No: 34 
 
S.No 
Name of the 
microorganism 
 
Zone of inhibition in mm 
Extract of Acalypha indica Linn. 
A B C D E 
    1 Staphylococcus aureus 
(NCIM 2079) 
11 10 24 - 34 
2 Bacillus subtilis 
(NCIM 2063) 
12 12 09 - 12 
3 
 
Pseudomonas 
aeruginosa 
(NCIM 2036) 
15 12 22 - 23 
4 E. coli 
(NCIM 2065) 
15 12 32 - 42 
5 Klebsiella pneumonia 
(NCIM 2098) 
14 12 38 - 45 
6 Aspergilus niger 
(NCIM 105) 
15 15 24 - 32 
7 Candida albicans 
(NCIM 3102) 
15 10 15 - 26 
 
A= high concentration; B=low concentration; C=patch; D= DMSO; E=standard (ciprofloxacin 
5µg/ disc for bacteria; Nystatin 100 µg/ disc for fungi) 
    
Observation 
 The anti- microbial activity for the given sample was carried out by disc diffusion 
technique (Indian pharmacopoeia 1996, vol II A-105). The test micro organism of 
Staphylococcus aureus, E.coli, Pseudomonas aeruginosa and Bacillus subtilis, Klebsiella and 
Fungus Aspergilusniger, Candida albicans were obtained from national chemical laboratory 
(NCL) pune and maintained by periodical sub culturing on nutrient agar and sabouraud dextrose 
agar medium for bacteria and fungi respectively. The effect produced by the sample was 
compared with the effect produced by the positive control (reference standard Ciprofloxacin 
5µg/ disc for bacteria; Nystatin100µg/ disc for fungi). 
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For Bacteria 
 After 24hrs the plates are observed. The zone of inhibition was calculated by measuring the 
minimum dimension of the zone of no bacterial growth around the hole. The Figures are shown 
in  54,55,56,57,58 and results are in Table No: 34. 
For Fungi 
  After 72hrs the plates are observed. The zone of inhibition was calculated by measuring 
the minimum dimension of the zone of no fungal growth around the hole. The figures are shown 
in 52, 53 and the results are shown in Table  No: 34. 
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8.1. SUMMARY AND CONCLUSION 
 
 Nine patches (P1, P2, P3, H4, H5, H6, S7 S8 and S9) of Methanolic Extract 
of Acalypha indica Linn. Transdermal Patches were prepared by Solvent Casting 
Technique. 
 
 Various formulation parameters, polymer (Pectin, HPMC and Sodium 
alginate) ratios and permeation enhancers (SLS and DMSO) were optimized to get 
thin, transparent, smooth, stable and high permeable Transdermal Patch. 
 
 The FTIR graphs of drug, excipients and formulations showed that there is 
no extra peak (or) broadening of peaks were observed and thus it indicates that there 
is no incompatibility between drug and excipients. 
 
 From the optimization, best 3 formulations of Pectin, Sodium alginate, 
HPMC (P2, H4 and S7) were selected based on folding endurance and optimal 
tensile strength. 
 
 When the amount of polymer was less than 0.4gm or greater than 0.4gm the 
folding endurance of the patch was affected. If the quantity less than 0.4gm handling 
of the patch was very difficult and if the quantity was greater than 0.4gm, the patch 
become thick or break with insignificant tensile strength. 
 
 0.3 ml of DMSO was selected as permeation enhancer to produce flexible 
patch without having major influence on their release property. 
 
 0.3 ml of glycerin was added as a plasticizer and to produce a flexible patch 
without having major influence on their release property. If the amount exceeds, the 
patch loses its flexibility and become stiff, hence the above two variables were 
controlled to form a good patch. 
 
 The plasticizer diffuses through the patch and softens the polymer particles. 
This softening promotes latex coalescence and patch formation. 
 
 
 All batches were evaluated for % Moisture uptake, % Moisture content, 
Thickness, Folding endurance, % Drug content, Percent elongation, Tensile strength. 
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 Among these, the formulation H4 showed maximum % Moisture uptake 
(3.57), % Moisture content (3.27), Thickness (0.35mm), folding endurance (265), % 
Drug content (96.24), Percent elongation (97), Tensile strength (7.66 Kg mm2). 
 
No significant difference in drug content was observed between the patches 
among the three formulations. 
 
 The in-vitro release profile of  Transdermal Patch formulation of  Extract of 
Acalypha indica  Linn. for  P2 (85.24%), H4 (70.56%), and S7 (84.41%) at the end 
of 12 hours study.  
 
The release behavior of drug from the patch formulation exhibited a biphasic 
pattern, which is characterised by faster onset of action and slower sustained release.  
 
The data obtained from in-vitro release profile after 12 hours was fitted with 
various kinetic equations to determine the mechanism of drug release and release 
rate as indicated by higher correlation coefficients (r2). The drug release from patch  
formulation follows zero order and non-fickian diffusion.  
 
These findings indicates that the drug release from the formulated patch were 
diffusion controlled.  
 
 To confirm the release mechanism, the data of H4 (65.56%) release were 
applied to Korsmeyer peppas equation to find out the release exponent ‘n’, which 
indicates the mechanism of drug diffusion from the patch formulation. The data 
were fitted with equation as indicated by higher correlation coefficients (r2) and 
mechanism was found to be non-fickian diffusion (anomalous transport). 
 
 The kinetic data of H4 formulation was best fitted to Korsmeyer peppa’s 
model and the value of regression coefficient, r = 0.984 and n = 0.83 which follows 
non-fickian, Super case-II transport.  
 
From the results of in-vitro release and physicochemical studies, H4 
(HPMC) was concluded as best formulation. So, H4 was subjected to further 
evaluation such as ex- vivo and stability studies.  
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The ex-vivo studies results showed 65.56% of drug release at the end of 12 
hours. It concluded the sustained release property of polymer, through the skin  
 
Stability study was performed for the  period of three months. The 
physicochemical parameters like visual appearance, colour, texture and drug content 
and drug release were studied. The results showed that there is no significant change 
from its initial nature till the period of three months at 40˚C ±2˚C/75± 5% RH. Also 
the screening anti microbial studies confirmed the antimicrobial activity of the 
formulation. 
The present work has achieved the objectives of formulation of Transdermal 
patch of Methanolic Extract of Acalypha indica Linn. by using different polymers 
like Pectin, Sodium alginate and HPMC. It showed appreciable amount of 
permeation through the skin (ex-vivo) and sustained release for the period of 12 
hours. The release kinetics confirms that the formulation followed zero order,      
non-fickian diffusion model.   
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